Characterization of Morphine Self-Administration Following Spinal Cord Injury by Woller, Sarah Ann
  
CHARACTERIZATION OF MORPHINE SELF-ADMINISTRATION 
FOLLOWING SPINAL CORD INJURY 
 
 
A Dissertation 
by 
SARAH ANN WOLLER  
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
Chair of Committee,    Michelle A. Hook 
Committee Members,   James W. Grau 
   Rajesh Miranda 
   Jianrong Li 
Intercollegiate Faculty Chair,  Jane Welsh 
 
August 2013 
 
Major Subject: Neuroscience 
 
Copyright 2013 Sarah Ann Woller
  ii 
ABSTRACT 
  
 Approximately two-thirds of patients will experience pain following spinal cord 
injury (SCI).  This pain can arise as an immediate consequence of SCI, or can develop 
over time into chronic, neuropathic pain. Individuals are frequently prescribed opioid 
analgesics, including morphine, for the treatment of pain in both the acute and chronic 
phases of SCI.  Yet, despite the prevalence of opioid use, no studies have examined the 
addictive potential of opioids, or their secondary effects, following spinal injury.   
 These experiments used a clinically relevant self-administration paradigm to 
examine both addiction and functional recovery after morphine administration.  To 
assess morphine administration in the acute phase of SCI, animals were placed in 
operant chambers 24-hours following spinal injury.  In the chambers, depression of a 
reinforced lever resulted in an intravenous infusion of morphine (or vehicle).  Animals 
were placed in the chambers for 7, 12-hour sessions and could administer up to 30 mg of 
morphine per session.  Morphine self-administration was also examined in the chronic 
phase of injury.  Animals were placed into operant chambers for 7, 12-hour sessions 
beginning 14 or 35 days after injury.  The amount of morphine administered, as well as 
recovery of locomotor function and general health, was compared across subjects with 
SCI and sham (no injury) controls.  
 In the acute phase of injury, SCI significantly reduced self-administration of 
morphine, but administration led to decreased recovery of locomotor function and 
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weight loss.  In the chronic phase of injury, self-administration did not differ between 
contused and sham animals.  All subjects administered the full amount of morphine 
available each day.  In this phase of injury, morphine administration led to significant 
weight loss, but did not attenuate recovery of locomotor function. 
 These studies suggest that spinal injury reduced the addictive potential of 
morphine in the acute, but not the chronic, phase of SCI.  However, acute administration 
of high doses of morphine decreased recovery of locomotor function. Morphine should 
not be used in this phase of injury for the clinical treatment of pain.  In the chronic 
phase, opioid use must be closely monitored as use may result in addictive behavior.  
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CHAPTER I1 
INTRODUCTION AND LITERATURE REVIEW 
Overview 
 Spinal cord injury (SCI) results in numerous consequences affecting both 
physical and mental health.  The most significant physical deficits resulting from injury 
are loss of sensation and paralysis.  Despite loss of sensation, however, the majority of 
people will experience pain as a result of injury.  For most, this pain will develop into 
severe or excruciating neuropathic pain within five years of injury (Siddall et al., 2003).  
This pathological pain has been shown to significantly decrease quality of life (Celik et 
al., 2012), and has been linked to a lower self-rating of general health (Siddall et al., 
2003), stress (Störmer et al., 1997), and depression (Harden & Cohen, 2003; Wetering et 
al., 2010; Cairns et al., 1996).  Given the significant impact pain has in this population, it 
is important that it be properly managed.  Nonetheless, neuropathic pain remains 
difficult to treat and often requires clinicians to take a trial-and-error approach to pain 
management.  Moreover, one of the most effective treatments for this pain, opioids and 
specifically morphine, are highly addictive in uninjured populations.  Yet, there have 
been no empirical studies addressing the addictive potential for morphine following SCI.  
Studies of this nature are important because morphine cannot simply be removed as a 
treatment option when patients experience intractable pain, and consequently the injured 
population is maintained on high doses of opioids for long periods of time. It is 
                                                
1 Reprinted with permission from “Opioid administration following spinal cord injury: 
implications for pain and locomotor recovery” by S.A. Woller & M.A. Hook, 2013. 
Experimental Neurology, in press. Copyright (2013) by Elsevier. 
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imperative that we understand how injury can affect the addictive potential of opioids, 
and effects secondary to pain relief.     
 The experiments in this dissertation will investigate the addictive potential of 
morphine following SCI in a rodent contusion model.  Use of a rodent model of SCI 
paired with a self-administration paradigm will allow for the assessment of abuse 
liability in the presence of both nociceptive and neuropathic pain.  In addition, the 
effects of morphine on recovery of locomotor function, the development of pathological 
pain, and general health will be studied.  This introduction will provide an overview of 
SCI, and the treatment of pain following injury.  Then, the consequences of opioid 
administration following SCI, specifically addiction, attenuation of locomotor recovery, 
and the development of pathological pain, will be discussed. Finally, the specific aims of 
this dissertation will be outlined.  
Spinal Cord Injury and the Development of Pain 
 The development of pain is a significant consequence of SCI.  It has been 
estimated that in the period of time immediately following the injury, 11-94% of people 
will experience pain not only as a result of the injury itself, but also from peripheral 
injuries sustained in unison, as in the case of a motor vehicle accident (Störmer et al., 
1997; Fenollosa et al., 1993; Donnelly & Eng, 2005; Cardenas et al., 2004; Siddall et al., 
2003; Finnerup et al., 2001; Ravenscroft et al., 2000; Siddall & Loeser, 2001).  
Unfortunately, this pain is known to develop through a number of pathways, and is yet to 
be fully explained.  Pain can result from the loss of cells, and the secondary processes 
initiated as a result of the mechanical trauma.  For instance, traumatic injury to the spinal 
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cord results in the immediate death of neurons, glia, and endothelial cells at the impact 
site.  Over time, continued apoptosis is caused by a number of secondary processes all 
set in motion by the initial impact, including increased levels of excitatory amino acids, 
disruption of calcium concentration, production of nitric oxide (NO), oxidative stress, 
and continued immune activation.  The loss of cells resulting from any of these 
processes can directly or indirectly influence the development of pain following injury.  
For instance, the loss of serotonergic fibers decreases descending inhibition, resulting in 
hyperexcitation of dorsal horn neurons, contributing to the development of pain (Hains 
et al., 2003).  
 Spinal cord injury results in cell loss occurring via necrosis, a primary effect of 
injury or via apoptosis, a secondary pathology.  Necrosis is characterized by cellular 
swelling, membrane lysis, release of intracellular contents, and the launch of an 
inflammatory response (Cohen, 1993; Majno & Joris, 1995).  Apoptosis, on the other 
hand, is a programmed cell death characterized by cell shrinkage and phagocytic 
engulfment of dead cells.  Apoptosis, as a result of trauma, is initiated by the release of 
cytochrome c from the mitochondria and the activation of procaspase-9, which, together, 
lead to the activation of caspase-3 (Springer et al., 1999; Sekhon & Fehlings, 2001).  
Activation of this apoptotic pathway has been demonstrated following SCI (Springer et 
al., 1999), resulting in the loss of GABAergic (Bao & Liu, 2003; Rafati et al., 2008; Sah 
et al., 2002; Sharma & Sjoguist, 2002) and serotonergic fibers to induce the loss of 
motor function and the development of pain (Hama & Sagen, 2012; Gwak & 
Hulsebosch, 2011; Meisner et al., 2010; Costigan et al., 2009). 
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 Similarly, apoptosis leads to the release of pro-inflammatory cytokines and 
induces migration of immune cells to the injury site (Kang et al., 1997; Seino et al., 
1997; Desbarats et al., 2003; Letellier et al., 2010).  The immune response begins with 
the infiltration of neutrophils, monocytes, macrophages, microglia, and lymphocytes.  
This immune response, while completely necessary following injury, is often detrimental 
(Schwartz, 2003).  In fact, astrocytes and microglia express many of the same receptors 
and release many of the same factors as neurons, marking them as prime contributors to 
the development of neuropathic pain following SCI (Gwak & Hulsebosch, 2011; Pineau 
& Lacroix, 2007; Porter & McCarthy, 1997; Wang et al., 2009; Jarvis, 2010).  Normally, 
microglia are present in a resting state, but in the presence of interleukin (IL) -6, 
adenosine triphosphate (ATP), substance P, or fractalkine, among others, microglia 
become activated (Gwak et al., 2012; Hulsebosch et al., 2009), resulting in a 
morphological and functional change (Soulet & Rivest, 2008).  Microglia are activated 
within minutes of CNS injury and normally function to remove debris and damaged cells 
(Kreutzberg, 1996; David et al., 1990; Avellino et al., 1995; Fleming et al., 2006; 
Carlson et al., 1998).  However, these cells can remain activated for weeks to months 
following injury and contribute to continued damage and cell death via the release of 
glutamate, ATP, calcitonin gene-related peptide (CGRP), pro-inflammatory cytokines, 
reactive oxygen species (ROS), NO, and proteases (Kreutzberg, 1996; Aloisi, 2001; 
Dong & Benveniste, 2001; Fleming et al., 2006; Carlson et al., 1998; Lieberman et al., 
1989; Priller et al., 1995; Rischke & Krieglstein, 1991; Stanley et al., 1994; Svensson et 
al., 1993).  Several of these factors (e.g. increased extracellular glutamate, pro-
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inflammatory cytokines) have been associated with the development of pain via 
sensitization of sensory circuits (Bennett et al., 2000a, b; Detloff et al., 2008).  This 
persistent, dysfunctional glial reaction, termed “gliopathy” (Hulsebosch, 2008), is 
thought to contribute to central pain following injury (Costigan et al., 2009). 
 Astrocytes have also been shown to contribute to “gliopathy.”  Activated within 
24 hours of spinal cord injury, astrocytes can remain active for months to years (Schnell 
et al., 1999; Popovich et al., 1997).  Under normal circumstances, astrocytes are 
responsible for maintaining glutamate homeostasis, and preventing excitotoxicity 
(Lepore et al., 2011).  However, following injury, astrocytic activation leads to the 
activation of MAPK pathways.  These pathways can activate the nuclear transcription 
factor, NF-κB (nuclear factor κB), which subsequently results in increased production of 
pro-inflammatory cytokines, chemokines, prostaglandins, NO, free radicals, neurotoxins, 
and excitatory amino acids (Hameed et al., 2010).  These substances, as with those 
released from microglia, are pain-mediating and, in a cyclic manner, contribute to 
continued neuronal hyperexcitability following injury (Detloff et al., 2008; Hulsebosch 
et al., 2009; Keane et al., 2006; Scholz & Woolf, 2007; Vallejo et al., 2010). 
 The toll-like receptor (TLR) has also been found to play a role in the 
development of pain.  TLRs are a collection of 13 single transmembrane receptors 
normally expressed on microglia and, in response to inflammation, on astrocytes.  TLRs 
are believed to activate pathways similar to those activated by IL-1, eventually leading 
to the activation of NF-κB, and resulting in the production of pro-inflammatory 
cytokines (e.g. IL-1β and TNFα).  A role for this pathway is well established in the 
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initiation and maintenance of chronic pain (Milligan & Watkins, 2009; Nicotra et al., 
2012).  In particular, the TLR4 pathway has been well defined (see Hutchinson et al., 
2011; Hameed et al., 2010; Nicotra et al., 2012).  Briefly, ligand binding to the TLR4 
results in activation of phosphoinositide 3-kinase (PI3K) and Akt, which can lead to 
apoptosis via the caspase-3 pathway.  In addition, downstream activation includes 
mitogen activated protein kinase (MAPK), NFκB, and tumor necrosis factor (TNFα), 
which lead to the release of pro-inflammatory cytokines and the development of 
allodynia.  Like the IL-1 pathway, this pathway is relevant to the development of pain 
(Nicotra et al., 2012; DeLeo et al., 2004; Raghavendra et al., 2003; 2004; Tanga et al., 
2005).  In support of this, blocking the TLR4 is able to prevent (Bettoni et al., 2008) and 
reverse neuropathic pain in an experimental setting (Hutchinson et al., 2007, 2008, 
2010).  In an SCI model, TLRs activate a number of signaling cascades, which affect the 
pathophysiology of secondary injury processes (Kigerl & Popovich, 2009), but the role 
of TLR4 in producing pain following SCI remains to be determined. 
 Many pathways have been found to play a role in the development of neuropathic 
pain following spinal cord injury.  While neuronal pathways were thought to primarily 
contribute to the development of pain, increasing evidence supports a role of glia.  
Further investigation of the underlying mechanisms will allow for better, more specific 
treatments (with fewer side effects) for pain following SCI. 
Treatment of Pain Following Spinal Cord Injury 
Clinicians are faced with the challenge of properly managing and treating the 
various types of pain that develop after SCI.  Not surprisingly, relief of chronic pain is a 
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high priority to the spinally injured.  In fact, when a quadriplegic population was 
surveyed, 15-20% indicated that the relief of chronic pain, which develops in up to two-
thirds of people, would most improve their quality of life (Siddall et al., 2003; Anderson, 
2004). This number is almost equal to the percentage indicating restoration of locomotor 
function as a priority (Anderson, 2004).  Although a considerable amount of research has 
focused on preventing the development of pain, and developing effective treatments, it 
remains difficult to treat (Heutink et al., 2012).  Currently, chronic pain is treated with a 
variety of pharmaceuticals including opioids, antidepressants, anticonvulsants (e.g. 
gabapentin), non-steroidal anti-inflammatory drugs (NSAIDs), and N-methyl-D-
aspartate (NMDA) antagonists (Xu & Yaksh, 2011; Cruccu, 2007; Teasell et al., 2010; 
Finnerup et al., 2010; Finnerup & Baastrup, 2012).  While all show varying efficacy, 
morphine has long been considered a standard treatment in pain relief.  Indeed, opioids 
are among the most effective treatments for neuropathic pain, and are commonly trialed 
for analgesic efficacy (Clark, 2002; Liang et al., 2008; O’Connor & Dworkin, 2009; 
Przwlocki & Przewlocki, 2005; Sindrup & Jensen, 1999; Widerstron-Noga & Turk, 
2003; Warms et al., 2002). 
 For many years, opioid analgesics were considered to be a first-line medication 
for the treatment of neuropathic pain.  Now, these medications are considered to be a 
second-line treatment (Attal et al., 2010; Dworkin et al., 2010).  This change is the result 
of concern surrounding the presence of adverse side effects, a lack of evidence 
demonstrating long-term safety of use, evidence showing continuous use is often 
associated with the development of dependence, tolerance, opioid-induced hyperalgesia, 
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and / or addiction, and a lack of placebo-controlled trials assessing the efficacy of opioid 
treatment following SCI (Dworkin et al., 2007; Ballantyne & LaForge, 2007; Ballantyne 
& Mao, 2003; O’Connor & Dworkin, 2009; Trescot et al., 2008; Attal et al., 2009).  In 
fact, it is known that, in the long term, approximately 20% of people will discontinue 
opioid treatment (Moore & McQuay, 2005), because of significant side effects such as 
respiratory depression, constipation, nausea, vomiting, sedation, dizziness, and headache 
(reviewed in Dellemijn, 1999; Cruccu, 2007; Dworkin et al., 2007).  Notably 80% of 
patients will continue to use opioids, however, leaving them vulnerable to the potential 
development of addiction. In addition to these side effects, it has been demonstrated in 
both animal models and human studies that administration of analgesics such as 
morphine can potentiate the development of neuropathic pain and allodynia (Chang et 
al., 2007; Hook et al., 2007; Liang et al., 2008; Yu et al., 1997a, 1997b).   
 The lack of evidence regarding safety is particularly concerning when opioid 
analgesics are administered following SCI.  Emerging evidence suggests that opioid 
administration can interact with spinal cord injury pathology to negatively impact 
locomotor recovery, the development of pain, and general health.  These are concerns 
that are not always present in an uninjured population, but warrant investigation in the 
injured population.  In a similar manner, the processes occurring after spinal cord injury 
are likely to influence the development of addiction.  The following sections will discuss 
the consequences of opioid administration following spinal cord injury, focusing on the 
development of addiction, effects on recovery of locomotor function, and the 
development of pathological, paradoxical pain. 
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Consequences of Opioid Administration After SCI: Addiction 
 Traditionally, opioid receptor agonists are known for their analgesic 
(antinociceptive) and rewarding, hedonic properties.  This is evidenced by their frequent 
use in the treatment of pain, and the common occurrence of abuse following recreational 
or therapeutic use.  In fact, it is estimated that 18-45% of individuals using opioids for 
the management of chronic pain will abuse the drug (Ballantyne & LaForge, 2007; 
Compton & Volkow, 2006; Contet et al., 2008; Heinemann et al., 1992; Morasco & 
Dobscha, 2008; Trescot et al., 2008).  Inconsistencies between reports of the incidence 
of addiction in the clinic, resulting in this wide range, stem from differences in 
definitions of abuse, methods of reporting, and populations being surveyed, along with a 
general lack of empirical research examining the efficacy of long-term opioid use and 
addictive potential (Bell & Salmon, 2009; Dersh et al., 2008; Hojsted & Sjogren, 2007; 
Morasco & Dobsha, 2008; Radnitz & Tirch, 1995).  Some reports indicate that these 
estimates of opioid abuse are low, whereas others suggest they are high.  As noted, the 
fluctuation in incidence may depend on the characteristics of the population being 
sampled.  For example, including depressed individuals in these surveys of drug misuse 
paints a very different picture.  Depressed individuals are not only prescribed opioids 
more frequently, but are also given higher doses of opioids (Koyyalagunta et al., 2013; 
Blanco et al., 2013; Dobscha et al., 2013).  This is concerning as there is a reported 
increased incidence of depression in individuals with spinal cord injury (Bonanno et al., 
2012; Al-Owesie et al., 2012; Migliorini et al., 2009; Bombardier et al., 2012).  Given 
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the estimates of abuse and various factors that may contribute to abuse liability, the use 
of opioids for the management of pain must be further investigated. 
 Opioid analgesics are commonly trialed for efficacy in the period of time 
immediately following the injury (the acute phase) and as a long-term treatment for 
pathological pain (the chronic phase).  In the acute phase of injury, opioid analgesics are 
used to treat nociceptive pain, which will resolve with healing, making the period of 
opioid use relatively short.  Addiction has not typically been studied in this phase of 
injury.  Previous experiments from our lab have, however, assessed the addictive 
potential of morphine in the acute phase of SCI using a conditioned place preference 
paradigm (Woller et al., 2012).  In these studies, animals were given a contusion or sham 
injury or remained intact.  Two days following injury, animals began conditioning: they 
were placed in a distinct context paired with an injection of morphine (2.5 mg/kg, i.p.) or 
in a separate context paired with saline.  Animals received two context drug pairings (for 
both morphine and saline) over two days.  When the preference was tested, interestingly, 
contused animals developed a stronger preference for the morphine-paired chamber than 
sham or intact controls, suggesting the contusion injury is increasing the addictive 
potential for morphine in this phase of injury.  As this preference was based on just two 
drug-context pairings, the increased preference underscores the potential for addiction 
even with short-term use in the acute phase of SCI. 
 In the chronic phase of injury, opioids are used to manage neuropathic pain.  This 
pain is often described as severe or excruciating and does not resolve with time.  In this 
case, long-term use of opioids is expected.  A review of cases of human opioid treatment 
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of chronic pain, however, revealed a low risk of dependence (Minozzi et al., 2013).  
Similarly, reports from extant literature suggest that a state of neuropathic pain decreases 
the addictive potential of opioids.  Niikura and colleagues (2008) used a sciatic nerve 
ligation to induce neuropathic pain in rats.  They found that the rats experiencing pain 
did not develop a conditioned place preference for morphine.  Martin et al. (2007) also 
found rats experiencing neuropathic pain will self-administer less morphine than their 
pain free counterparts, at low doses.  Additionally, they examined the rewarding effect 
of opioids using an intracranial self-stimulation paradigm and found the hedonic 
properties of morphine are reduced in rats experiencing neuropathic pain (Ewan & 
Martin, 2011).  These studies would suggest the development of addiction is not a 
concern when opioids are used to treat neuropathic pain, but this is in contrast to reports 
of opioid addiction and abuse of opioid analgesics.  Even though the addictive nature of 
opioids is well documented, little work has been done to examine the addictive potential 
of morphine following SCI. 
 Following SCI, molecular processes underlying the pathology of the injury may 
influence addiction.  Specifically, the κ-opioid receptor (KOR) system is thought to play 
a role.  Typically, this system is considered to be anti-reward.  Activation of KOR, 
through increased dynorphin levels, has been shown to counter opioid-induced 
analgesia, and is known to counter the rewarding properties of drugs of abuse (Lutz & 
Kieffer, 2013; Wang et al., 2010).  Following exposure to social or physical stressors, as 
spinal cord injury can be, there is an increase in activation of the KOR system (Lutz & 
Kieffer, 2013; Bruchas et al., 2010).  This same activation has been demonstrated with 
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extended exposure to drugs of abuse, such as morphine (Lutz & Kieffer, 2013; Butelman 
et al., 2012; Wang et al., 1999).  This would suggest morphine administration in the 
acute phase of spinal cord injury is likely to be less rewarding because the rewarding 
properties are being countered by activation of the KOR system.  This may decrease the 
addictive potential of morphine following spinal cord injury. 
 However, this same system has been implicated in drug relapse, and may 
contribute to addiction (Chavkin, 2012; Wang et al., 2010).  Clinically, not all 
individuals with a spinal cord injury are drug-free.  In fact, Heinemann et al. (1988) 
found that up to 62% of SCI patients had misused drugs or alcohol at the time of their 
injury.  This suggests that the injury, along with stress-induced increases in dynorphin, 
could increase the addictive potential of morphine in patients with previous history of 
drug abuse.  Indeed, stress-related increases in dynorphin have been linked to increased 
conditioned place preference for cocaine and nicotine (McLaughlin et al., 2003, 2006; 
Schindler et al., 2010, 2012; Smith et al., 2012), and have been associated with increased 
risk of drug abuse in people (de Kloet et al., 2005).  Thus, activation of the KOR may 
induce drug-seeking behavior. 
 Numerous complex processes are known to underlie the development of 
addiction.  Some of these may be changed following injury, and in the transition 
between acute and chronic pain.  Understanding how these variables will affect addiction 
after SCI is critical. 
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Consequences of Opioid Administration After SCI: Attenuation of Locomotor 
Recovery 
 Addiction is not the only concern surrounding the use of opioid analgesics for the 
treatment of pain resulting from a spinal cord injury.  Recent experimental evidence 
from our laboratory has demonstrated that a single, intrathecal (i.t.) administration of 
morphine 24-hours after spinal cord injury significantly attenuates recovery of 
locomotor function (Hook et al., 2009; 2011).  In these experiments, animals received a 
moderate contusion injury and an intrathecal catheter was implanted.  The next day, the 
extent of spared locomotor function was evaluated using the Basso, Beattie, Bresnahan 
(BBB) scale (Basso et al., 1995).  All animals had equivalent scores and were divided 
into one of three groups: a vehicle, 30 µg, or 90 µg morphine group.  Morphine was 
administered through the catheter, and recovery was monitored for 21-days.  At the end 
of the recovery period, the animals that had received 90 µg morphine showed 
significantly lower locomotor recovery than those receiving saline, indicating that 
morphine administration is undermining recovery of locomotor function.  With the 
exception of these recent studies by Hook (2009; 2011), the effects of exogenous opioid 
administration on recovery of locomotor function after SCI have received little attention. 
 The lack of experimental research is concerning because there is significant 
evidence that opioids may act synergistically with SCI to exacerbate cell death and 
decrease recovery of locomotor function.  In the acutely injured spinal cord, glutamate 
levels increase in minutes, and return to normal within 1.5 hours (McAdoo et al., 2005).  
It is thought that, while dying cells can continue to release glutamate over days, the 
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levels are not high enough to contribute significantly to excitotoxicity (McAdoo et al., 
2005).  However, compounding this increase in glutamate levels through the 
administration of morphine (Lim et al., 2005), it is possible that SCI and opioid 
administration in the early phase of SCI can exacerbate and sustain neuronal (Lepore et 
al., 2011; Nottingham & Springer, 2003) and/or oligodendrocytic (Xu et al., 2004; 
McTigue, 2008; Almad et al., 2011) cell death, which could undermine recovery of 
locomotor function following injury.   
Indeed, experimental evidence suggests agonists for the KOR and µ-opioid 
receptor (MOR) can have detrimental effects on locomotor function, by inducing central 
sensitization.  For instance, it is known that intrathecal administration of dynorphin, an 
endogenous ligand for the KOR (Zhang et al., 1998), or intrathecal dynorphin A (2-17), 
a stable metabolite of dynorphin, induce long-lasting paralysis in intact rats (Headrick et 
al., 1995; Caudle & Isaac, 1987; Faden, 1990; Faden & Jacobs, 1983; Hemstapat et al., 
2009).  For example, Faden & Jacobs (1984) conducted a series of experiments in which 
they administered dynorphin peptides intrathecally and quantified the effects on motor 
function.  They found dose-dependent decrements in motor function produced by 
dynorphin (1-17), dynorphin (1-13), dynorphin (1-8), and α-neo-endorphin.  This 
hindlimb paralysis was evident within 10 minutes of administration, and was not blocked 
or reversed by naloxone administration (Faden & Jacobs, 1984).  Further studies 
demonstrated that spinal levels of dynorphin increase with the severity of SCI (Faden et 
al., 1985), and following prolonged morphine administration (Mao et al., 2002).  
Moreover, inflammatory pain, such as that resulting from SCI, results in upregulation of 
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spinal dynorphin (Nahin et al., 1989; Ruda et al., 1988; Przewlocki et al., 1992).  The 
paralysis and loss of tail flick reflex resulting from dynorphin activity are NMDAR-
dependent (Caudle & Isaac, 1987; Long et al., 1987; Faden & Simon, 1988; Faden 1992; 
Woods & Zagen, 2001; Hemstapat et al., 2009), and treatment with a selective, 
noncompetitive NMDAR antagonist prior to dynorphin administration lessens resultant 
paralysis (Bakshi et al., 1992).  Similarly, dynorphin potentiates NMDA currents (Lai et 
al., 1998) and increases internal calcium ion concentrations leading to enhanced 
neuronal loss.  These effects are blocked by the NMDAR antagonist MK-801 (Hauser et 
al., 1999).  This result implicates NMDAR in producing negative effects on locomotor 
function.  Overall, whether increased by morphine administration or SCI, dynorphin is 
leading to paralysis via excitotoxicity. 
 Spinal cord injury also activates an immune response reminiscent of that 
produced with opioid administration.  Interleukin (IL)-1β, a pro-inflammatory cytokine 
released from microglia has been identified as a key player affecting locomotor function 
following SCI (Nesic et al., 2001).  IL-1β is expressed within 15-min following injury in 
a rodent model of SCI, and is one of the first cytokines released by activated microglia 
(Kim et al., 2006; Pineau & Lacroix, 2007).  While it has been demonstrated that IL-1β 
levels increase as a result of injury, exacerbating these levels is likely to produce further 
trauma.  In fact, intrathecal administration of IL-1 β for three days in intact rats causes 
significant and lasting motor deficits that are blocked by the concurrent administration of 
IL-1ra (Liu et al., 2008).  Similarly, morphine administration has been shown to increase 
spinal levels of IL-1β in contused rats, relative to vehicle controls (Hook et al., 2011).  
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As with the application of IL-1β, increased IL-1β levels resulting from morphine 
administration yielded an attenuation of locomotor recovery (Hook et al., 2011).  
Antagonizing the IL-1 receptor before morphine administration blocked morphine-
induced locomotor deficits in SCI rats (Hook et al., 2011).   Experimental evidence 
indicates IL-1β can induce apoptosis by phosphorylation of p38 MAPK, activating the 
pro-apoptotic caspase-3 cascade (Mika, 2008; Springer et al., 1999). Furthermore, 
cytokines, such as IL-1β, can activate both cytochrome c and caspase 9, which lead to 
activation of the pro-apoptotic caspase-3 pathway.  Cell death initiates the release of pro-
inflammatory cytokines, NO, and reactive oxygen species (Block & Hong, 2005; Min et 
al., 2003, 2004; Cho et al., 2011), causing further, sustained activation of microglia, 
enhancing the pro-inflammatory environment of the injured spinal cord, and affecting 
locomotor recovery after SCI. 
 There are many routes by which opioid administration can exacerbate the 
pathology of spinal cord injury to contribute to increased loss of locomotor function.  
Morphine administration may increase glutamate availability, leading to excitotoxic cell 
death, Similarly, morphine will lead to activation of MOR and KORs and NMDARs, 
which can also induce processes initiating excitotoxicity.  In addition, there is an 
increase in the levels of pro-inflammatory cytokines occurring as a result of injury and 
opioid administration, which lead to activation of apoptotic pathways, and sustained glial 
activation.  Many of these same pathways can contribute to paradoxical pain. 
  
  17 
Consequences of Opioid Administration After SCI: Paradoxical Pain 
 There is emerging evidence that opioid administration not only affects locomotor 
recovery, but also affects neuronal and glial systems to produce pathological pain.  
Indeed, the continuous administration of morphine can lead to the development of pain 
sensitization known as opioid-induced hyperalgesia (OIH; Mao, 2002; Lee et al., 2011).  
Opioid-induced hyperalgesia, has been observed following administration of intrathecal 
(i.t.) morphine (Mao et al., 1995), a fentanyl bolus (Célèrier et al., 2000), and with 
repeated heroin administration (Célèrier et al., 2001).  Increasing the dose of the opioid 
does not relieve this pain; instead, relief requires a seemingly contradictory decrease in 
the dose (Lee et al., 2011).  While the causal mechanisms for OIH are still largely 
unknown, the glutamatergic system and increased spinal dynorphin have emerged as 
important mediators (Mao et al., 2002; Silverman, 2009; Lee et al., 2011; Mayer et al., 
1999).  For instance, it has been suggested that central sensitization, resulting from 
excessive NMDAR activation can lead to the development of hyperalgesia (Costigan et 
al., 2009).   
 The development of OIH is related to increased NMDAR activation stemming 
from 1) increased NMDAR excitability and 2) increased glutamate availability.  It is 
known that glutamate can cause persistent activation of NMDA receptors, leading to 
pathological pain (Jacquet, 1988b; Raigorodsky & Urca, 1987; Mao et al., 1994; Laulin 
et al., 2002).  Similarly, repeated exposure to morphine increases NMDAR channel 
activation (Harris et al., 1996; Croul et al. 1998; Mao & Mayer, 2001).  In support of 
this, treatment with an NMDA antagonist enhanced morphine analgesia (Mehta et al., 
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2011).  In addition, meeting the second criteria, chronic morphine administration can 
lead to the downregulation of spinal glutamate transporters, which increases glutamate 
availability (Lim et al. 2005).  This additional glutamate availability, along with 
NMDAR excitation, increases NMDAR activation (Mao et al., 2002; Harris et al., 1996; 
Croul et al. 1998; Mao & Mayer, 2001).  Activation of the NMDAR through 
hyperexcitation has been shown to produce pain and neuronal cell death by apoptosis 
(Mao et al., 1992; Mao et al., 1997). 
 As with recovery of locomotor function, a role of spinal dynorphin has also been 
established in OIH (Mao, 2002; Lee et al., 2011).  Sustained morphine administration 
results in increased spinal levels of dynorphin (Vanderah et al., 2001), which are already 
increased as a result of SCI.  Dynorphin is often pronociceptive (Cho & Basbaum, 1989; 
Caudle & Isaac, 1988; Kjander et al., 1990; Wang et al., 2001; Dubner & Ruda, 1992), 
and the release of this endogenous opioid can lead to the development of pain via the 
induction of central sensitization (Vanderah et al., 2000). 
 As discussed previously, glial cells also play a significant role in the 
development and maintenance of persistent pain following central nervous system 
(CNS) injury (Graeber & Christie, 2012; Graeber, 2010; Hulsebosch et al., 2009; 
Watkins et al., 2007; Re & Dubner, 2010; Gosselin et al., 2010; Graeber & Streit, 2010; 
Mika et al., 2013).  Suter et al. (2007), for example, outlined potential glial-induced 
mechanisms involved in pain following injury (nerve, SCI, inflammation, etc.).  It is 
important to note that various types of pain are manifest following injury, each with 
unique and shared mechanisms (for review, see Hulsebosch et al., 2009).  Generally 
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speaking, however, microglia become activated in response to factors produced by 
damaged cells and contribute to pain states through their recruitment to the spinal cord 
dorsal horn (Gwak et al., 2012).  Activation of microglia is positively associated with 
severity of allodynia following a moderate SCI or spinal nerve ligation (Detloff et al., 
2008).  Similarly, opioid-dependent activation of astrocytes and microglia affects the 
release of excitatory amino acids, nitric oxide (NO), reactive oxygen species (ROS), pro-
inflammatory cytokines (e.g. IL-1β, TNFα), chemokines, and prostaglandins 
(Raghavendra et al., 2002; Aloisi, 2001; Dong & Beveniste, 2001; DeLeo et al., 2004).  
Of the pro-inflammatory cytokines, IL-1β, specifically, is known to be increased 
following morphine administration (Hook et al., 2011), and has been shown to induce 
allodynia and hyperalgesia when delivered intrathecally (i.t.) (Mika et al., 2008; Obreja 
et al.,2002; Opree & Kress, 2000). Glial activation alone can lead to neuronal 
hyperexcitability, neurotoxicity, and chronic inflammation, however, these effects, as 
they are initiated by SCI and interact with opioid administration, have not been 
examined.  Evidence suggests that SCI and opioid administration, in combination, can 
lead to the development of pain through shared pathways (Woller & Hook, 2013). 
Specific Aims 
 Experimentally, a rodent model of contusion injury is used to simulate the 
traumatic injury typically seen in humans (Sekhon & Fehlings, 2001).  This rodent 
model of SCI relies on numerous behavioral tests to assess not only the development of 
pain, but also the recovery of locomotor function.  Using these behavioral tests, it has 
been shown that a contusion injury produces symptoms of neuropathic pain in up to 80% 
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of rodents (Hulsebosch, 2002), compared to the estimated 66% of people that will 
experience similar pain characteristics.  This makes the rodent contusion model 
clinically relevant in the study of pain.  In addition, the rodent model of SCI can be used 
to assess the analgesic and addictive properties of drugs.  The self-administration 
paradigm is commonly used to assess addiction in rodents, and in the case of SCI, 
simulates patient controlled analgesia.  However, despite the clinical relevance, there 
have been no studies of addiction in this model of injury.  It is important that an animal 
model is developed and used to delineate the potential for addiction after SCI, as well as 
the contribution of confounding factors such as pain or depression.  With this in mind, 
the experiments in this dissertation are designed to characterize morphine self-
administration following a spinal cord injury.   
An animal model of SCI provides a unique opportunity to examine the addictive 
potential of morphine in a state of nociceptive pain and over the course of the 
development of neuropathic pain.  In the acute phase of injury, defined here as days 1-7 
post injury, animals are experiencing nociceptive pain as a result of the surgery itself.  It 
is known that this pain resolves with healing and is well managed with opioid analgesics.  
Despite the frequent use for the treatment of pain, however, the addictive potential of 
morphine is not typically studied in this phase, or when opioids are being used to treat 
nociceptive pain.  Thus, the first experiments (Aim I, Chapter III) will examine 
morphine self-administration in the acute phase of injury.  In the early chronic phase of 
spinal cord injury, neuropathic pain is beginning to develop, and is well established in 
the late chronic phase.  This pain does not resolve, and often gets worse, with time.  The 
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abuse liability of morphine has been studied in cases of neuropathic pain, but not 
neuropathic pain resulting from a spinal cord injury.  Aim II (Chapter IV), therefore, will 
examine the addictive potential of morphine in the early (days 14-20) and late (days 35-
42) chronic phases of spinal cord injury.  In addition to characterizing the addictive 
potential of morphine in the acute and chronic phase of injury, these studies will 
examine secondary effects of morphine administration.  In both the acute and chronic 
phases of injury, recovery of locomotor function and weight loss will be examined.   
We hypothesize that morphine acts synergistically with molecular process 
occurring after spinal cord injury to contribute to attenuated recovery of locomotor 
function and the development of pain (Woller and Hook, 2013).  This possibility will be 
addressed in the final aim (Aim III, Chapter V).   
 The discussion from the sections above can be tied together in one concept 
(Table 1) demonstrating the interactions of opioid administration with the environment 
of the spinal cord following injury, which can produce alterations in the addictive 
potential of morphine, decrease recovery of locomotor function, and lead to the 
development of pain.  It is unlikely that any one factor is solely responsible for these 
detrimental effects.  Rather, imposing opioid administration onto the vulnerable, injured 
spinal cord is likely to exacerbate and compound effects seen in either case individually, 
to produce pathology.  Thus, this idea hinges on a few key components: increased 
glutamate, increased dynorphin levels, and increased release of pro-inflammatory 
cytokines.  Each of these components has been shown to have various negative effects 
following opioid administration and spinal cord injury individually, but have not been 
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examined in combination.  To begin to test this hypothesis, Aim III will examine the 
development of opioid-induced hyperalgesia, the development of tolerance, and changes 
in protein levels of TNFα, MOR, KOR, caspase 3, TLR2, and TLR4 occurring after 
chronic morphine administration. 
  
  23 
 
 
 
  
Ta
bl
e 
1:
 C
om
m
on
al
iti
es
 o
f o
pi
oi
d 
ad
m
in
ist
ra
tio
n 
an
d 
SC
I. 
Th
e 
co
ns
eq
ue
nc
es
 o
f s
pi
na
l c
or
d 
in
ju
ry
 a
nd
 
op
io
id
s a
dm
in
is
tra
tio
n 
ar
e 
lis
te
d 
al
on
g 
w
ith
 th
e 
m
ec
ha
ni
sm
s c
om
m
on
 to
 b
ot
h.
 
C
on
ce
qu
en
ce
 o
f S
C
I o
r o
pi
oi
d 
ad
m
in
is
tra
tio
n
M
ec
ha
ni
sm
s 
co
m
m
on
 to
 S
C
I a
nd
 o
pi
oi
d 
ad
m
in
is
tra
tio
n
D
ec
re
as
ed
 lo
co
m
ot
or
 fu
nc
tio
n
E
xc
ito
to
xi
c 
ce
ll 
de
at
h
In
cr
ea
se
d 
ex
tra
ce
llu
la
r g
lu
ta
m
at
e
In
cr
ea
se
d 
N
M
D
A
R
 a
ct
iv
at
io
n
In
cr
ea
se
d 
dy
no
rp
hi
n 
le
ve
ls
In
cr
ea
se
d 
gl
ia
l a
ct
iv
at
io
n
R
el
ea
se
 g
lu
ta
m
at
e,
 A
TP
, C
G
R
P,
 p
ro
-in
fla
m
m
at
or
y 
cy
to
ki
ne
s,
 R
O
S
, N
O
A
po
pt
os
is
In
iti
at
ed
 v
ia
 a
ct
iv
at
io
n 
of
 c
as
pa
se
-3
, i
nc
re
as
ed
 B
ax
 a
nd
 d
ec
re
as
ed
 B
cl
-2
C
au
se
s 
re
le
as
e 
of
 p
ro
in
fla
m
m
at
or
y 
cy
to
ki
ne
s
P
ai
n 
de
ve
lo
pm
en
t
C
en
tra
l s
en
si
tiz
at
io
n
In
cr
ea
se
d 
N
M
D
A
R
 a
ct
iv
ai
to
n
In
cr
ea
se
d 
ex
tra
ce
llu
la
r g
lu
ta
m
at
e
O
pi
oi
d-
in
du
ce
d 
hy
pe
ra
lg
es
ia
In
cr
ea
se
d 
N
M
D
A
R
 a
ct
iv
ai
to
n
In
cr
ea
se
d 
gl
ut
am
at
e 
av
ai
la
bi
lit
y
In
cr
ea
se
d 
sp
in
al
 d
yn
or
ph
in
In
cr
ea
se
d 
gl
ia
l a
ct
iv
at
io
n
R
el
ea
se
 g
lu
ta
m
at
e,
 A
TP
, C
G
R
P,
 p
ro
-in
fla
m
m
at
or
y 
cy
to
ki
ne
s,
 
R
O
S
, N
O
, a
ct
iv
at
io
n 
of
 M
A
P
K
 p
at
hw
ya
s,
 T
LR
's
A
dd
ic
tiv
e 
po
te
nt
ia
l
In
cr
ea
se
d 
dy
no
rp
hi
n 
le
ve
ls
A
ct
iv
at
io
n 
of
 T
LR
s
  24 
CHAPTER II 
GENERAL METHOD 
Subjects 
 Male, Sprague-Dawley rats obtained from Harlan (Houston, TX) were used as 
subjects.  Animals were 90-110 days old (300-350 g), and were individually housed in 
Plexiglas bins [45.7 (length) x 23.5 (width) x 20.3 (height) cm] with food and water 
available ad libitum.  Subjects’ bladders were expressed manually in the morning (8-
9:30 AM) and evening (6-7:30PM) until they regained bladder control, which was 
defined as three consecutive days with an empty bladder at the time of expression.  
Animals were maintained on a 12-hour light-dark cycle.  Except where noted, all 
behavioral testing occurred during the light portion of the cycle. 
 All of the experiments were reviewed and approved by the institutional care 
committee at Texas A&M and all NIH guidelines for the care and use of animal subjects 
were followed. 
Surgery 
Jugular Catheterization  
To allow for the self-administration of morphine, animals were implanted with a 
jugular catheter.  Rats were anesthetized using a combination of 80 mg/kg ketamine and 
10 mg/kg xylazine, intraperitoneally (i.p.).  While under anesthesia, a catheter consisting 
of a length of polyethylene (PE) 50 tubing was inserted into the jugular vein and tied to 
the vein.  Using an 11-gauge stainless steel tube as a guide, the catheter was passed 
subcutaneously through the body of the animal so that it exited in the back.  A back 
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mount cannula pedestal (model 313-00BM-10-SPC; Plastics One Inc., Roanoke, VA) 
was implanted subcutaneously and connected to the catheter.  The back mount exited the 
skin between the scapulae and was covered with a dust cap.  All incisions were closed 
using VetBond. 
 For the first 24-hours after surgery, the rats were housed in a recovery room 
maintained at 26.6°C.  All subjects were treated (IP) with 100,000 U/kg penicillin G 
potassium immediately after surgery and again 2 days later.  To help maintain hydration, 
the subjects were also given 3.0 ml of saline (0.9%, IP) following surgery.  During the 5-
day recovery period following surgery, the catheters were flushed with heparinized 
saline (0.25ml). 
Contusion Injury  
Five days after implantation of the jugular catheter, subjects were anesthetized 
with inhaled isoflurane (5% to induce anesthesia and 2-3% for maintenance), and an area 
approximately 4.5 cm above and below the injury site was shaved and disinfected with 
iodine.  A 7 cm incision was made over the spinal cord, and two incisions extending 3 
cm rostral and caudal to T12 were made on either side of the vertebral column.  The 
lamina of the T12 vertebra was removed, exposing the spinal tissue.  The vertebral 
column was then fixed within the MASCIS device (Constantini & Young, 1994; Gruner, 
1992).  Animals were given a moderate contusion injury by allowing the 10 g impactor 
(outfitted with a 2.5 mm tip) to drop 12.5 mm.  The wound was closed with Michel clips.  
Sham subjects received a laminectomy only, and intact subjects received anesthesia 
only. 
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 For the first 24-hours after surgery, the rats were housed in a recovery room as 
described previously.  All subjects were treated (IP) with 100,000 U/kg penicillin G 
potassium immediately after surgery and again 2 days later.  To help maintain hydration, 
the subjects were also given 3.0 ml of saline (0.9%, IP) following surgery. The Michel 
clips were removed 14 days following surgery. 
Self-Administration Procedure 
Apparatus  
Self-administration took place in operant chambers (model E10-10; Coulbourn, 
Allentown, PA) enclosed in sound-attenuating cubicles.  Each chamber was equipped 
with two levers with a stimulus light positioned over each.  Infusion pumps (Razel 
Scientific Instruments, Stanford, CT) controlled drug delivery to each of the boxes, and a 
20 ml syringe delivered an IV infusion (160 µl) over a 6-second timeframe.  The 
chambers were interfaced with two IBM computers, which controlled drug delivery and 
recorded lever depressions. 
Self-Administration Procedure  
All animals were implanted with a jugular catheter, and 5 days later received a 
contusion or a sham injury or remained intact.  Twenty-four hours following the 
contusion or sham surgery, locomotor function was assessed (see Assessment of Motor 
and Sensory Recovery) and the animals were placed in the self-administration chambers 
for 12-hours. In the chambers, depression of the right lever (FR1) resulted in an IV 
infusion of 0.0, 0.75, 1.5, or 3.0 mg morphine (equivalent to 0.56, 1.13, or 2.26 mg 
morphine base), with a maximum total dose of 30 mg morphine / day.  This dose is 
  27 
similar to what is used clinically in humans.  Patients receive up to 120 mg/kg morphine 
a day at the beginning of treatment (30 mg is between 75-120 mg / kg  / day; Chu et al., 
2006), with doses increasing as needed for pain relief, often up to 180 mg morphine / kg 
/ day (Clark, 2002; Schneider & Kirsh, 2010).  We recorded the amount of morphine 
administered for the first 7 days following injury. 
 In addition to the amount of morphine administered, we examined the rate of 
administration.  The computers recorded the time (min) between each lever depression.  
These times, accounting for just the reinforced lever depressions, were summed, and 
separated into 1-hour time bins.  The cumulative number of reinforced lever depressions 
made each hour was then multiplied by the dose administered to yield the cumulative 
amount of morphine administered by hour. 
Assessment of Motor and Sensory Recovery 
Locomotor Recovery 
Locomotor behavior was assessed using the Basso-Beattie-Bresnahan (BBB) 
rating scale (Basso et al., 1995) in an open enclosure (99 cm diameter and 23 cm deep) 
on the day following the contusion injury.  The subjects were acclimated to the apparatus 
for 5 min per day for 3 days prior to surgery.  Twenty-four hours after surgery, each 
subject was placed in the open field and observed for 4 min to assess locomotor 
function.  All observers had high intra- and inter-observer reliability (all r’s >0.89), and 
were blind to the subjects’ experimental treatment. 
Locomotor scores were transformed to help assure that the data were amendable 
to parametric analyses (Ferguson et al., 2004).  This transformation pools BBB scores 2-
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4, removing a discontinuity in the scale.  The transformation also pools scores from a 
region of the scale (14-21) that is seldom used for a moderate contusion injury.  By 
pooling these scores, we obtain an ordered scale that is relatively continuous with units 
that have approximately equivalent interval spacing.  Meeting these criteria allows us to 
apply metric operations (computation of mean performance across legs), improves the 
justification for parametric statistical analyses, and increases statistical power. 
Girdle Reactivity 
A grid map of the girdle zone for allodynic responding was made on the rats 
using an indelible marker (44 squares). A single von Frey filament with bending force of 
204.14 mN (26 g force) was applied to each point on the grid, and vocalization responses 
were recorded on a grip map of that animal. For each subject, the total number of 
vocalizations were recorded (Nv) and normalized by the following formula: percent 
vocalizations=(Nv x 100)/total number applications (44). 
Tactile Reactivity 
Reactivity was assessed using von Frey stimuli formed 
from nylon monofilaments (Semmes-Weinstein Anesthesiometer; Stoelting Co., 
Chicago, IL) and applied to the plantar surface of the hindpaws. Subjects were placed 
into Plexiglas tubes [7.0 cm (internal diameter) x 20 cm (length)] that had 6 cm (length) 
x 1.7 (width) cm notches removed from the sides, to allow the hindlimbs to hang freely. 
After a 15-min acclimation period, the von Frey stimuli were applied sequentially at 
approximately 2 sec intervals until subjects withdrew the paw and vocalized. If no 
response was observed, testing was terminated at a force of 300 g. Each subject was 
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tested twice on each foot in a counterbalanced ABBA order. Test sequences were spaced 
2 min apart. Stimulus intensity was reported using the formula provided by 
Semmes-Weinstein: Intensity= log10 (10,000*g force). 
Thermal Reactivity 
Thermal reactivity was assessed using radiant heat in the tail flick test. Subjects 
were placed in clear Plexiglas tubes with their tail positioned in a 0.5 cm deep groove, 
cut into an aluminum block, and allowed to acclimate to the apparatus (IITC Inc., Life 
Science, CA) and testing room for 15 min. The testing room was maintained at 26.5˚C. 
Thermal thresholds were then assessed. Thermal reactivity was tested using a halogen 
light that was focused onto the rat's tail. Prior to testing the temperature of the light, 
focused on the tail, was set to elicit a baseline tail flick response in 3-4 sec (average).  
This pre-set temperature was maintained across all subjects.  In testing, the latency to 
flick the tail away from the radiant heat source (light) was recorded. If a subject failed to 
respond, the test trial was automatically terminated after 8 s of heat exposure, to avoid 
tissue damage. Two tests occurred at 2-minute intervals, and the second test tail flick 
latencies were recorded as indices of nociceptive reactivity. To confirm that subjects did 
not respond in the absence of the stimuli, blank trials were also performed.  A ‘false 
alarm’ was recorded if subjects made a motor or vocalization response during the blank 
tests. The blank trials were performed 1 min before or after each sensory test (in a 
counterbalanced fashion).  No false alarms were recorded.   
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Western Blots 
Animals (n=12) were deeply anesthetized with pentobarbital (50 mg/kg) and a 1 
cm section of spinal cord around the lesion epicenter was rapidly removed.  To 
determine the spatial (dorso-ventral) changes, the spinal cord tissue was further 
sectioned to yield dorsal and ventral portions.  Total protein was extracted from the 
organic layer of the homogenized tissue containing protein and DNA using the 
QIAzol™ lysis reagent protocol for isolation of genomic DNA and/or proteins from fatty 
tissue (Qiagen, Valencia, CA).  Following determination of the protein concentration, 
using the Bradford Assay (BioRad, Hercules, CA), protein samples were diluted in 
Laemmli sample buffer and stored at -80°C at known concentrations (usually 2-5ug/ul).  
Western blotting was used for the protein quantification of µ-opioid receptor (MOR), κ-
opioid receptor (KOR), toll-like receptor (TLR) 2, TLR4, caspase 3, and TNFα.  Equal 
amounts (30ug) of total protein were subjected to SDS-PAGE using 15% Tris-HCl 
precast gels (BioRad, Hercules, CA) for TNFa (estimated molecular weight of ~17kDA), 
caspase-3 (multiple bands between ~35kDA and 10kDA), and KOR (estimated 
molecular weight of 50kDA) or 12% Tris-HEPES precast gels (Pierce, Rockford, IL) for 
TLR4 (estimated molecular weight of 102kDA), TLR2 (estimated molecular weight of 
100kDA), and MOR (estimated molecular weight of 50kDA).  Following transfer onto 
PVDV membranes (Millipore, Bedford, MA), the blots were blocked for one hour in 5% 
blotting grade milk (BioRad, Hercules, CA) in Tris-Buffered Saline Tween-20 (TBST). 
After blocking, the blots were incubated overnight at 4
o
 C in one of the following 
primary antibodies generated in rabbit: TNFα  (1:500; #ARC3012 - Invitrogen, 
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Camarillo, CA), TLR2 (1:1000; #NBP1-95457- Novus Biologicals, Littleton, CO), 
TLR4 (1:500; sc-30002- Santa Cruz Biotechnology, Inc, Santa Cruz, CA), Caspase-3 
(1:1500; #NB100-56113- Novus Biologicals, Littleton, CO), MOR (1:400; sc-15310- 
Santa Cruz Biotechnology, Inc, Santa Cruz, CA), KOR (1:750; #NB100-91902, Novus 
Biologicals, Littleton, CO), or Actin (~43 kDA, 1:5000; ab8227- Abcam Inc., 
Cambridge, MA). With the exception of Actin, all primary antibodies were diluted in 
blocking solution.  
The following day, blots were washed in TBST (3 x 10 min) at room temperature 
then incubated in HRP-conjugated goat anti-rabbit secondary antibodies (1:5,000; 
#31460; Pierce, Rockford, IL) for 1 hour at room temperature. Following another 3 x 10 
min series of washes, the blots were developed with ECL (Pierce, Rockford, IL) and 
imaged with Fluorchem HD2 (ProteinSimple, Santa Clara, CA). Ratios of the integrated 
densitometry of each protein of interest to the loading control (actin) were calculated, 
normalized to sham vehicle controls and averaged for animals within each group.  
Histology 
In this experiment, animals (n=24) were deeply anesthetized with pentobarbital 
(50 mg/kg) and perfused intracardially with phosphate buffered saline (PBS) followed 
by 4% paraformaldehyde in PBS.  A 1 centimeter section of spinal cord surrounding the 
lesion center was removed and post-fixed in 4% PFA for 2 hours and then transferred to 
30% sucrose for cryoprotection.  Following a minimum of 72 hours in sucrose, the 
section of cord was frozen in a cryomold with optimal cutting temperature (OCT) 
compound.  Twenty microns (20µm) horizontal sections were cut with a cryostat (Leica 
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Microsystems, Buffalo Grove, IL).  Sections were then used for staining with cresyl 
violet for Nissl substance and luxol fast blue for myelin (Beattie, 1992; Behrmann et al., 
1992). 
Slides containing sections of spinal cord were placed in a 1:1 chloroform/ethanol 
solution for 3 hours, and were then washed in 95% ethanol for 5 minutes.  Slides were 
put in Luxol Fast Blue overnight in a 50
 o
 C oven.  The following day, slides were rinsed 
in 95% ethanol, and were then quickly rinsed in distilled water (dH2O).  Slides then went 
through a series of washes: 1 minute in lithium carbonate, 1 min in 70% ethanol, quick 
rinse in dH20.  These steps were repeated until the sections were light blue.  Next, slides 
were placed into cresyl violet for 1 min.  Slides were then rinsed in dH2O and 
dehydrated for coverslipping.  
In these sections, the total cross-sectional area of the cord and spared tissue was 
assessed at the lesion center using MicrobrightField software as described by Hook et al. 
(2011).  Sections ±600, 1200, 1800, and 2400 µm from the lesion center (rostral and 
caudal) were also traced and analyzed.  Assessments were made by an experimenter who 
was blind to the subject’s treatment condition.  Three indices of lesion magnitude were 
derived: lesion, residual gray matter, and residual white matter.  To determine the area of 
lesion, an observer who was blind to the experimental treatments traced around the 
boundaries of cystic formations and areas of dense gliosis (Hook et al., 2011).  Nissl-
stained areas that contained neurons and glia of approximately normal densities denoted 
residual gray matter.  White matter was judged spared in myelin-stained areas lacking 
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dense gliosis and swollen fibers.  These analyses yielded three parameters for each 
section: white matter area, gray matter area, and lesion area. 
 To control for variability in section area across subjects, we applied a correction 
factor derived from our sham vehicle animals.  This correction factor is based on section 
widths and is multiplied by all area measurements to standardize area across analyses 
(see Grau et al., 2004).  By standardizing areas across sections we were able to estimate 
the degree to which tissue is “missing” (i.e. tissue loss from atrophy, necrosis, or 
apoptosis).  An accurate assessment of the degree to which a treatment has impacted, or 
lesioned, the cord includes both the remaining “damaged” tissue as well as resolved 
lesioned areas.  When we sum the amount of “missing” tissue and the measure 
“damaged” area we derive an index of the relative lesion (% relative lesion) in each 
section that is comparable across sections. We can also compute the relative percent of 
gray and white matter remaining in each section, relative to sham controls. 
Statistical Analyses 
 Comparisons between the amounts of morphine administered across 
surgery/dose/phase of injury, as well as the effects of morphine on recovery of function 
and molecular endpoints were analyzed using analysis of variance (ANOVA) and trend 
analyses.  In experiments with a continuous independent variable (e.g. recovery period, 
rostral-caudal histological sections), mixed-design ANOVAs were used.  In cases where 
significant between-subject differences were obtained (main effect of a single variable), 
group means were compared using the Duncan’s New Multiple Range Test (p < .05).  A 
non-parametric Kruskall-Wallace test was used to compare levels of the cleaved 
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caspase-3 band across groups. There does not appear to be a linear relation between 
levels of caspase-3 and the degree of apoptosis. Instead, numerous studies suggest that 
cell death will occur only when caspase activity reaches a critical threshold (Florentin 
and Arama, 2012). By ranking the levels of caspase-3 expressed across subjects and 
groups, the Kruskall-Wallace test allows for allows for a statistical comparison based on 
ranks of expression levels; a group expressing a higher level (mean rank) of expression 
would be more likely to surpass the critical threshold, and initiate cellular apoptosis. 
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CHAPTER III 
SELF-ADMINISTRATION OF MORPHINE IN THE ACUTE PHASE OF 
INJURY 
 As mentioned in the introduction, we have examined the addictive potential of 
morphine in the acute phase of SCI using a conditioned place preference (CPP) 
paradigm.  In this previous study, contused animals developed a greater preference for a 
morphine-paired chamber at both a 1.25 and 2.5 mg/kg (i.p.) dose of morphine compared 
to sham and intact controls (Woller et al., 2012).  This result suggests contused animals 
find morphine to be more rewarding.  Why reward is increased in injured animals, 
however, is less clear.  In the acute phase of injury, contused animals are experiencing 
pain as a result of injury.  Thus, contused animals could be developing a preference for 
the analgesic properties associated with morphine administration.  Indeed, the CPP 
paradigm has been used to assess spontaneous pain, and rats will develop a preference 
for a chamber paired with a pain-relieving drug (Navratilova et al., 2013). Critically, 
these pain-relieving drugs (e.g. clonidine) do not support a place preference in pain-free 
animals (Navratilova et al., 2013; King et al., 2009).  The traditional view, using this 
paradigm, however, is that animals develop a conditioned place preference for the 
hedonic properties of morphine.  This view suggests that contused animals may show an 
increased preference because spinal cord injury potentiates addiction.  It is important to 
note, though, that after SCI both the analgesic and hedonic properties could be 
considered to be rewarding.  This is an issue that must be further addressed. 
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In the current experiment, therefore, we used a self-administration paradigm to 
assess the rewarding properties of morphine following spinal cord injury.  This paradigm 
is commonly used to assess drug reward, and is thought to provide a better model of 
addictive behavior (Koob et al., 2009).  However, it has yet to be employed in the 
investigation of the addictive properties of drugs following spinal cord injury.  The aim 
of this experiment was to examine the amount of morphine self-administered following a 
moderate contusion injury.  The self-administration paradigm is also of clinical interest 
because it models patient-controlled delivery of analgesic agents (Martin et al., 2007; 
Sanchis-Segura & Spanagel, 2006).  Based on the results of previous experiments using 
the conditioned place preference paradigm, we hypothesized that contused animals 
would administer more morphine than sham and intact controls, suggesting that injury is 
potentiating addiction.  
Method 
 This experiment used a total of 12 rats (n=4).  In this experiment, the surgeries 
and self-administration procedures are as described in Chapter II (General Method).  
Specifically for this study, sham, contused, and intact rats were placed into self-
administration chambers for 12-hours, during their dark cycle (9pm-9am) for the first 
seven nights following injury.  In the self-administration chambers, each lever 
depression resulted in the infusion of 1.5 mg morphine, and a total of up to 30 mg each 
session.  
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Results 
Morphine Administered   
We calculated the amount of morphine each subject self-administered based on 
the number of lever depressions, including only depressions when morphine was 
available (up to 20 presses in this dose).  Although there was a tendency for sham 
controls to display higher levels of pressing than contused, which is consistent with the 
amount of morphine administered, there was not a significant main effect of surgery 
condition (both F’s <2.44, p > .05).  As shown in Figure 1 A & B, all subjects generally 
exhibited an increase in morphine administration over days (F (6, 54) = 3.52, p < .05).  
Contrary to our hypothesis, however, contused rats exhibited the lowest levels of 
morphine self-administration, yielding a main effect of surgery condition (F (2, 59) = 
5.29, p < .05). No other differences were significant (p > .05).  
Effects of Injury on Morphine Self-Administration are Dose-Dependent 
 In the first experiment, we found contused rats self-administered significantly 
less morphine than sham injured animals.  However, there is considerable data to suggest 
that the effects of opioids depend on the dose, time, and route of administration (Yu et 
al., 1997a, 1997b). Therefore, this experiment examined whether the propensity for 
morphine administration after SCI is dose-dependent.  We hypothesized that contused 
animals would continue to self-administer less morphine than sham controls, but this 
may depend on the dose. 
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Method 
In this experiment, 32 animals (n=4) were implanted with a jugular catheter, and, 
five days later, were given a moderate contusion or sham injury (See General Method 
and Figure 2).  Twenty-four hours later, baseline tests of locomotor function were 
conducted.  The same day, animals were placed into self-administration chambers.  
Subjects were assigned to one of four groups based on their baseline locomotor score: 
0.0 mg, 0.75 mg, 1.5 mg, or 3.0 mg/infusion.  Baseline BBB scores were balanced across 
conditions. Irrespective of the morphine dose administered with each lever press, all 
subjects had access to a total of 30 mg morphine in each of the seven sessions. 
Results 
Morphine Administered  
Examining the number of reinforced responses made overall, it was shown that, 
as expected, morphine treatment led to an increase in responses on the reinforced lever 
(F (3, 24) = 3.55, p < .05).  Again, net responses on the reinforced lever were not 
significantly affected by surgery condition (both F’s < 2.49, p < .05).   
In this experiment, the amount of morphine administered was once again 
calculated by examining the number of reinforced lever presses.  Because the saline-
treated subjects received no morphine, they were omitted from this analysis (Figure 3).  
As observed in the previous experiment, a contusion injury reduced self-administration 
at the intermediate dose (1.5 mg; Figure 3C).  A lower dose of morphine led to a 
moderate level of self-administration in both groups (Figure 3B).  At a high morphine 
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Figure 1: Morphine self-administered in the acute phase of SCI. The amount of 
morphine administered is shown across the seven sessions (A). Animals with a 
contusion injury self-administered significantly less morphine than sham animals (B).  
Neither sham nor contused animals were different from intact controls.  * p < .05 Figure 
from Woller et al., 2012. 
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Figure 2: Experimental Timeline: Dose Response. Five days following the 
implantation of a jugular catheter, animals received a contusion or sham injury.  
24-hours later, they were placed into the self-administration chambers.  They 
were placed into the chambers for 7 consecutive nights and had access to either 
0.0, 0.75, 1.5, or 3.0 mg morphine, up to 30 mg each session.  
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Figure 3: The amount of morphine self-administered in the acute phase of injury is 
dependent on dose.  Panel A shows the average amount of morphine administered by 
each group.  Contused and sham animals self-administered the same amount of 
morphine in the 0.75 mg group (B).  As in the first experiment, when given access to 
the 1.5 mg concentration (C), contused animals, administered significantly less 
morphine than sham animals.  This same difference was seen for the first three days of 
administration in the 3.0 mg concentration (D).  After the third day of administration, 
however, contused animals began to self-administer an amount of morphine equal to 
the sham animals.  * p < .05 Figure from Woller et al., 2012. 
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concentration (Figure 3D), contused rats self-administered less morphine on days 1 and 
2, but not days 4-7.  An ANOVA yielded a significant main effect of drug dose and 
surgery (both F’s > 5.59, p < .05).  In addition, the amount of morphine administered 
varied across days and the change observed depended upon both drug and surgery 
condition (all F’s > 2.73, p < .05).  Post-hoc comparisons showed that contused rats 
given 1.5 mg of morphine administered less drug than sham-operated rats given the 1.5 
mg dose and both of the 3.0 mg treated groups (p < .05).  Contused and sham rats given 
0.75 mg of morphine administered less than sham-operated animals given 3 mg (p < 
.05).  No other differences were significant (p > .05).  
Rate of Administration  
In addition to the total amount of morphine administered, we examined the time 
it took animals to administer the morphine.  For each session, animals have access to 
morphine for 12 hours.  By examining the cumulative amount administered over each 
hour of the 12-hour session, we can infer the underlying cause of administration.  
Rapidly self-administering the full amount in a short period of time is indicative of 
addictive behavior.  In contrast, a low, steady amount of administration over the 12-hour 
session would suggest the animal is administering the morphine as needed for pain 
relief.   
Animals in the 0.0 mg group do not administer morphine, so the cumulative 
number of responses per hour, up to a maximum of 15 presses is indicated (Figure 4A).  
Over days, these animals showed a decrease in responding, but still make a few presses 
over several hours.  Animals in the 0.75 mg dose are not depicted.  At this low dose, 
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there was not a difference in morphine self-administration between contused and sham 
subjects, and we did not look at the rate data.  In the moderate, 1.5 mg dose, (Figure 4B) 
sham animals reached a plateau in responding on Day 1 by 6 hours, having self-
administered approximately 18 mg of morphine.  In contrast, contused animals ceased to 
respond around 3 hours, and 5 mg of morphine.   Neither group rapidly administered the 
entire amount available, and neither group shows signs of addictive behaviors at this 
time.  In fact, the curve for the saline sham animals and the morphine sham animals 
looks very similar.  This, however, changes over the course of the seven sessions.  By 
Day 7, sham rats are administering nearly the full amount available in approximately 8 
hours, whereas the saline animals have greatly decreased responding at this time.  The 
contused animals administering morphine at a level only slightly increased from Day 1.  
On day 7, they administer around 10 mg in 5 hours. 
In the high, 3.0 mg dose, Day 1 is very similar to that of the 1.5 mg dose.  Sham 
animals are administering more morphine in a shorter period of time, but contused 
animals administered < 10 mg over the course of 3 hours.  By day 7, there is a vast 
change in behavior.  Now, both the sham and injured animals are administering nearly 
the entire amount of morphine available in 3-4 hours.  This pattern begins to emerge 
around Day 5.  The full 30 mg of morphine administered is an amount of morphine in 
excess of that needed to sustain analgesia.  For example, to a 300g rat, 30 mg is 100 
mg/kg; typically 10 mg/kg (systemic) produces a robust analgesia for up to 6 hours in 
these animals. This rapid administration seen in the 3.0 mg animals is indicative of 
addiction (Figure 4C).  
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Figure 4: The cumulative amount of morphine administered by hour. The cumulative 
amount of morphine administered over the 12-hour sessions on days 1, 3, 5, and 7 are 
shown for the 0.0 mg (A), 1.5 mg (B), and 3.0 mg (C) groups.  In contrast to contused 
animals in the 1.5 mg dose, contused subjects administering 3.0 mg/infusion show signs 
of addictive behavior by day 7 of administration. 
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Locomotor Recovery 
Locomotor recovery was monitored for a 42-day period in both sham and 
contused animals.  Sham control animals received a maximum converted BBB score of 
12 on the day following surgery, and this remained unchanged throughout the period of 
recovery in both the vehicle and morphine groups.  They were, therefore, omitted from 
further analyses.  To assess the impact of morphine on recovery following a contusion 
injury, we divided the data into two phases: during the period of self-administration 
(days 1-7), and during the period of recovery (days 8-42).  BBB scores did not differ 
significantly on day 1 post-injury (F (3, 12) < 1.0, p > .05).  During the period of self-
administration, morphine treatment slowed recovery (Figure 5).  While an ANOVA 
showed the main effect of drug treatment was not significant (F (3, 12)= 2.40, p > .05), a 
trend analysis revealed a significant linear component (F = 6.66, p < .05).  Neither the 
quadratic nor cubic trends were significant (both F’s < 0.54, p > .05). 
During the recovery period, morphine treated rats continued to perform below 
the saline-treated controls.  Again, while the main effect of drug treatment was not 
significant (F (3, 12) = 3.05, p < .05), a trend analysis yielded a significant linear 
component (F= 7.72, p < .05).  Neither the quadratic nor cubic components were 
significant (both F’s < 0.43, p > .05).  Post-hoc comparisons of the group means showed 
that subjects who had received the highest concentration of morphine (3.0 mg) differed 
from the saline-treated controls (Figure 5B; p < .05).  No other differences were 
significant (p > .05).  
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Figure 5: Effects of morphine administration in the acute phase of SCI.  
Locomotor recovery scores are shown during the period of administration (gray 
box days 1-7) and during the recovery period (days 8-42).  Despite similar scores 
prior to morphine treatment, animals administering the 3.0 mg concentration of 
morphine never recovered to the same level as those administering saline.  Panel B 
shows the average converted BBB scores on Day 42.  * p < .05 Figure from 
Woller et al., 2012. 
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It is important to note that because these animals were self-administering 
morphine, the amount administered in each group and dose varied.  Morphine 
administration is likely to have an impact on locomotor recovery based on the total 
amount of morphine (mg/kg) administered rather than the dose administered (mg).  To 
control for these differences, locomotor recovery was examined based on the amount 
each animal administered compared to their body weight (mg/kg).  In doing this, it was 
found that animals administering on average above 50 mg/kg/day showed significantly 
decreased recovery relative to those administering less than 50 mg/kg/day and those 
administering saline (Figure 6).  Supporting these results, an ANCOVA revealed a 
significant Day x Amount of morphine interaction (F (11, 440) = 2.04, p < .05).  Post 
hoc analyses indicated animals administering the high amount of morphine recovered 
significantly less function than those administering the low amount, or no morphine (p < 
.05).    
Weight   
As with locomotor recovery, the impact of morphine on weight change was 
assessed in two phases.  Examining weight change during the period of self-
administration (days 1-7), we found that morphine treatment led to weight loss over days 
independent of surgery condition.  Supporting this, an ANOVA revealed main effects of 
drug treatment and day, as well as a Drug x Day interaction (both F’s > 6.51, p < .05).  
No other terms were significant (all F’s < 3.16, p >  .05). 
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Figure 6: Recovery of locomotor function is dependent on the 
amount of morphine self-administered.  Animals administering 
above 50 mg/kg/day on average showed significantly attenuated 
recovery of locomotor function relative to saline controls and 
those administering less morphine. * p < .05 Figure from Woller 
et al., 2012. 
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Figure 7: Effects of morphine administration on weight following SCI. Weights of 
sham (A) and contused (B) animals were monitored during the period of morphine 
administration (gray shaded areas) and during the period of recovery.  During the 
period of administration, all animals lost weight.  During the recovery period, a 
contusion injury increased weight loss.  This weight difference is emphasized in B 
with the addition of the final average weight of sham animals superimposed on the 
figure of contused weights (open triangles).  During the period of recovery, sham 
animals regained weight and there was no effect of morphine on the amount of weight 
gain.  Contused animals regained weight dependent on the concentration of morphine 
administered.  Subjects administering the 3.0 mg/morphine/lever press regained 
significantly less weight than as those administering saline, or low and moderate doses 
of morphine. 
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During the recovery period, the effect of morphine treatment on weight in the sham-
operated rats waned across days (Figure 7A).  As observed in prior studies (Hook et al., 
2007, 2009, 2011; Woller et al., 2012), contused rats gained less weight (Figure 7B) than 
sham controls.  While contused rats that received a low-to-moderate dose of morphine 
per lever press (0.75-1.5 mg) recovered weight to the same level as the saline-treated 
controls, subjects that had received the highest concentration (3.0 mg) exhibited poorer 
recovery of weight, and maintained a significantly lower weight than sham controls 
across recovery.  An ANOVA confirmed that the main effects of drug, surgery, and day 
were significant (all F’s > 3.48, p < .05).  In addition, the change in weight observed 
across days depended upon both drug and surgery treatment (all F’s > 1.90, p < .0001). 
The Drug x Surgery interaction was not significant (F (3, 24) < 1.89, p > .05). 
As with recovery of locomotor function, it is expected that, rather than the dose 
affecting weight loss most significantly, that the amount each animal was administering 
would be most important.  Here, we also grouped animals into a zero, low (< 50 
mg/kg/day morphine), and high (> 50 mg/kg/day) amount of morphine administered.  
We found that animals administering above 50 mg/kg/day showed greater weight loss 
than those administering less than 50 mg/kg/day (Figure 8).  An ANOVA supported 
these results showing a main effect of amount of morphine (F (2, 43) = 10.29, p < .05).  
In fact, post hoc analyses indicate animals administering a low amount of morphine were 
not significantly different from those in the saline group (p < .05). 
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Figure 8: Weight loss is associated with administration of high amounts of 
morphine. As with locomotor recovery, animals administering the most 
morphine showed the highest amount of weight loss, relative to animals 
administering saline and lower amounts of morphine. * p < .05 
  52 
Discussion 
In the acute phase of a spinal cord injury, contused subjects self-administered 
significantly less morphine than their sham counterparts.  This decreased self- 
administration was time- and dose-dependent.  Contused subjects given access to the 1.5 
mg dose of morphine self-administered significantly less morphine than their sham 
counterparts on days 3-7 of recovery.  This was not the case for the higher (3.0 mg) 
dose.  Contused animals rapidly administered the total amount of morphine available at a 
rate commensurate with sham controls. This rapid administration in the 3.0 mg dose 
group provides evidence that the decreased self-administration in the 1.5 mg group is not 
related to locomotor deficits or an inability to perform the response.  In fact, 
administration of the high dose (3.0 mg) significantly undermined locomotor recovery, 
yet these animals were able to administer the entire amount available each session.  
Together, this suggests that the addictive potential of morphine is shifted in the acute 
phase of injury, but it is not negated.  These results suggest that molecular processes 
occurring after a contusion injury are reducing the addictive potential of morphine in this 
phase of injury. 
While our CPP results showed an increase in addictive potential in the acute 
phase of injury, we did not see the same effect using a self-administration paradigm.  
Morphine administration would be expected to engage neural systems associated with 
pleasure, and mechanisms that function to inhibit pain.  We have shown that the dose of 
morphine used to induce a conditioned preference also produces robust antinociception.  
For this reason, injured rats may prefer the morphine-paired context because nociceptive 
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input (pain signals) is inhibited.  In the absence of pain (sham and intact rats), the 
antinociceptive effect of morphine may have little reward value (with the low doses used 
in the present study), and as a result, yield only a weak preference for the morphine-
paired context.  However, just as humans will self-administer an opiate to bring pain 
relief, we would expect injured rats to maintain a level of opiate infusion sufficient to 
diminish tonic pain.  Indeed, injured rats given access to the low (0.75 mg) and moderate 
(1.5 mg) concentrations of morphine administered approximately 10 mg/kg of morphine 
over the 12-hour training period, a dosage that would be sufficient to maintain 
antinociception for approximately 6 hours (the half life of morphine is 2-3 hours) if it 
were given in one administration.  However, individual administrations (with each lever 
press) of the low (0.75 mg) and moderate (1.5 mg) doses may not provide sufficient 
analgesia with each administration for the animals to continue responding (thus allowing 
larger amounts of morphine to accumulate).  This may explain the reduced 
administration seen in the contused groups administering 0.75 mg and 1.5 mg relative to 
sham controls treated with 1.5 mg of morphine, and both groups treated with the 3.0 mg 
dose. 
Although motivational variables remain to be determined, the behavior of the 
sham rats treated with the higher doses of morphine is suggestive of addiction.  In a self-
administration task, addictive behavior is evident from the near-maximal responding to 
obtain the full amount of opiate available.  Inspection of the amount of morphine taken 
by sham-operated rats indicated that an addictive tendency emerged at a moderate 
concentration (1.5 mg), and was fully evident at the high concentration (3.0 mg).  
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Injured rats did not engage in the same level of addictive behavior, and even at the high 
concentration of morphine, this effect did not emerge until late in training.  Following 
injury there are several underlying molecular changes occurring that may cause the shift 
in addictive potential seen in contused animals.  Activation of the KOR has been thought 
to oppose morphine-induced analgesia, and has been associated with a decreased 
preference for a morphine-paired context (Suzuki et al., 1999).  Following injury, there 
is an increase in the amount of dynorphin, the endogenous ligand for the KOR, 
commensurate with injury severity.  Activation of the KOR might mask the rewarding 
effects of lower doses of morphine although it may not be sufficient to counter the 
rewarding effects associated with higher doses. 
Another potential explanation for the decreased self-administration seen in 
contused animals involves the inflammatory response to injury.  Immediately following 
SCI, there is an increase in the number of lymphocytes, microglia, and astrocytes at the 
injury site (Ankeny & Popovich, 2009; Ankeny et al., 2006; Alexander & Popovich, 
2009).  It is now generally accepted that microglia and astrocytes play a role in the 
development of chronic and neuropathic pain (See Mika et al., 2013 for review).  
Interactions of these cell types, along with the release of pro-inflammatory cytokines are 
thought to contribute to a loss of opioid analgesic efficacy (DeLeo & Yezierski, 2001; 
Mika, 2008; Watkins et al., 2003).  In addition, microglial expressing the non-classic 
opioid receptor, TLR4, are activated within 72 hours of SCI (Kigerl et al., 2007), and 
this activation is further increased by chronic morphine administration (Cao et al., 2010).  
Spinal cord injury, TLR4 activation, and morphine administration all increase mRNA 
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and protein levels of the pro-inflammatory cytokine IL-1β in spinal cord tissue 
(Hutchinson et al., 2008b; Liu et al., 2008; Lewis et al., 2010; Hook et al., 2011), which 
could modulate opioid effectiveness (Hutchinson et al., 2008; 2011) by increasing pain 
and reducing analgesic efficacy, and this process could contribute to injury-induced 
changes in opiate self-administration. 
Increased levels of pro-inflammatory cytokines could also undermine locomotor 
recovery.  In this study, administration of the high dose of morphine (3.0 mg) 
significantly undermined recovery of locomotor function.  The low, 0.75 mg, and 
moderate, 1.5 mg, doses, however, had no effect. These data concur with our previous 
studies showing that the administration of a high amount of i.t. morphine (90 µg) 
significantly attenuated recovery of locomotor function, but a moderate (30 µg) amount 
had no effect (Hook et al., 2009; 2011).  These data also extend our previous studies by 
showing that morphine is not just having an effect when applied directly to the spinal 
cord, but can also impact recovery of locomotor function when applied via an 
intravenous route, which is typically utilized clinically.  Importantly, the amount these 
animals administer, even in the high condition, is low relative to the amount used 
clinically for the treatment of pain.  SCI patients will receive up to 180 mg /kg a day, 
with doses increasing as necessary for the management of pain (Magrinelli et al., 2013).  
As noted above, increased pro-inflammatory cytokine levels and other molecular 
changes inherent to SCI and opioid administration may result in decreased locomotor 
recovery.  As discussed in the Introduction (Chapter I), increases in the levels of IL-1β 
following injury have been linked to a decrease in recovery of locomotor function.  Both 
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SCI and morphine administration have been shown to increase levels of pro-
inflammatory cytokines (Hook et al., 2011), and increased expression of IL-1β appears 
to be necessary for the morphine-induced attenuation of recovery after SCI. It has been 
suggested that these motor deficits related to increased IL-1β are the result of glutamate 
toxicity and increased neuronal loss (Liu et al., 2008).  Through activation of the KOR 
or increased glial activation, and increased glutamate levels, it is possible that SCI and 
opioid administration in the early phase of injury can exacerbate and sustain neuronal 
(Lepore et al., 2011; Nottingham and Springer, 2003) and/or oligodendrocytic (Almad et 
al., 2011b; McTigue, 2008; Xu et al., 2004) cell death, which could undermine recovery 
of locomotor function following injury.   
These changes occurring at a neuronal and glial level, and occurring in the acute 
phase of injury, can be synergistically exacerbated by the administration of morphine, 
which could lead to an attenuation of locomotor recovery (for review, see Woller & 
Hook, 2013). Alternatively, there is an increase in dynorphin levels in the acute phase of 
SCI.  This endogenous KOR agonist has been shown to play a role in the pathology of 
SCI (Krumins & Faden, 1986) and administration produces paralysis in intact rats 
through activation of the NMDAR (Bakshi et al., 1992). Morphine binding to the kappa 
receptor, on top of the increased levels of dynorphin resulting from the injury, may 
exacerbate neuronal loss, and lead to decreased recovery of locomotor function.  
Morphine administration also resulted in weight loss during the period of 
administration in both contused and sham subjects.  In injured animals, the high dose of 
morphine caused an increase in weight loss relative to the other doses.  Furthermore, as 
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with recovery of locomotor function, this effect was dependent on the amount of 
morphine being administered.  Chronic morphine administration is often associated with 
weight loss occurring as a result of decreased food intake (Nogueiras et al., 2012; 
Ferenczi et al., 2010).  In these animals, however, we did not see a difference in food 
intake during the period of self-administration (data not shown), when the most robust 
weight loss occurred.  Alternatively, weight loss can occur as a part of a withdrawal 
syndrome (Gu et al., 2005) or dehydration, which were not directly assessed in this 
study, but can be assessed further in future studies.   
 From a clinical perspective these data indicate that, it is important that patients 
are not given a high dose of morphine in the acute phase of SCI.  Administration of a 
high dose of morphine leads to an increase in addictive behavior, a decrease in 
locomotor recovery, and an increase in weight loss.  Low to moderate amounts of 
morphine, however, do not seem to produce to these same effects. 
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CHAPTER IV 
SELF-ADMINISTRATION OF MORPHINE IN THE CHRONIC PHASE OF 
INJURY 
The addictive potential of morphine varies depending on the experimental design 
(conditioned place preference or self-administration paradigm) and dose administered.  
Indeed, the previous study investigated morphine self-administration in the acute phase 
of injury and revealed dose-dependent effects.  Contused animals, when given access to 
a moderate dose of morphine (1.5 mg/ lever depression), self-administered significantly 
less morphine than their sham counterparts.  When given access to a higher 
concentration, 3.0 mg / lever depression, contused animals increased the amount of 
morphine administered over the first three days to self-administer nearly the full 30 mg 
available to them for each session in the final four days.  These results suggest there is a 
shift in the addictive potential of morphine in the acute phase of injury. 
As mentioned in the introduction, opiates are used for the treatment of both 
nociceptive pain in the acute phase of injury, and neuropathic pain, which develops in 
the chronic phase of SCI.  Anecdotally, abuse liability is said to be reduced when opioids 
are used for the treatment of neuropathic pain.  Indeed, there is evidence in both human 
and animal literature to support this claim (Minozzi et al., 2013; Ewan & Martin, 2011).   
However, individuals with a SCI are likely to develop conditions, such as depression, 
which further increase the prescription of opioids.  In addition, abuse liability has not 
been studied using a model of central neuropathic pain.  While this model of neuropathic 
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pain should be comparable to others, and show a reduction in addictive potential of 
morphine, this remains to be tested. 
In addition to examining the abuse liability of morphine in the chronic phase of 
injury, we are able to use the self-administration paradigm to examine the effects of 
repeated morphine administration on long-term recovery of function. Indeed, the 
previous study demonstrated that self-administration of morphine at amounts greater 
than 50 mg/kg/day significantly attenuated recovery of locomotor function when 
administration occurred from days 1-7 post SCI (Chapter III).  In the rodent model of 
contusion injury, we typically see a plateau in recovery of locomotor function at two 
weeks post injury (Hook et al., 2004).  Whether morphine administration would have a 
similar effect in this later phase of SCI has not been examined. 
To address these issues, the current study extends the original finding on the 
addictive potential of morphine, and the morphine-induced attenuation of locomotor 
recovery.  Here, the propensity for self-administration is examined in the chronic phase 
of SCI.  This is important because the contusion model of spinal cord injury typically 
leads to the development of neuropathic pain in approximately 80% of subjects 
(Hulsebosch, 2002).  However, signs of this pain do not begin to appear until around 14 
days following injury, with established neuropathic pain being present around 35 days 
post injury (Crown et al., 2006).  This study tests the hypothesis that a state of 
neuropathic pain lowers the addictive potential of morphine in the chronic phase of SCI. 
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Method 
In this experiment, 60 animals (n=6) were given a sham or contusion injury 5 
days after the implantation of a jugular catheter.  Twenty-four hours after the contusion 
injury, baseline tests of locomotor and sensory reactivity were conducted.  After 
balancing day 1 BBB scores, animals were divided into groups (Figure 9).  In one group, 
animals were placed into the self-administration chambers for 7 nights beginning 24-
hours after injury.  In the chambers, animals were given access to 0.0 or 1.5 mg 
morphine/ lever depression, up to 30 mg morphine/ session.  A second group of animals 
were placed into the self-administration chambers in the early chronic (Days 14-21) 
phase of injury.  As with the acute group, these animals were placed into the self-
administration for 12 hours during their dark cycle for 7 nights.  In the chambers, they 
were given access to 0.0 or 1.5 mg morphine/ lever depression, up to 30 mg morphine/ 
session.  Animals in the final group were placed in the chambers in the late chronic 
phase of injury (Days 35-41).  These animals had access to 1.5 mg morphine/ lever 
depression, up to 30 mg/session, for 7 sessions.  
Results 
Morphine Self-Administration is Decreased in the Acute Phase of Spinal Cord Injury 
Baseline Sensory Reactivity.  Twenty-fours following a contusion or sham 
injury, baseline sensory reactivity tests were conducted.  These tests measured 
mechanical allodynia, thermal hyperalgesia, and the development of at-level neuropathic 
pain (girdle test).  Using von Frey filaments to measure mechanical allodynia, we found  
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Figure 9: Experimental timeline: phase of injury.  In this experiment, animals were 
implanted with a jugular catheter, and received a contusion or sham injury 5 days later.  
One group of rats was placed into the self-administration chambers 24-hours following 
SCI, another group 14-days following SCI, and a third 35-days following SCI.  Each 
group had access to 1.5 mg morphine/ lever depression, up to 30 mg each session.    
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that sham animals withdrew their hindlimb at a lower threshold than contused animals (F 
(1, 22) = 17.87, p < .05, Figure 10A).  Vocalizations to the mechanical stimuli were also 
recorded.  Here, sham animals vocalized at a lower threshold than contused animals, but 
this result only approached significance (F (1, 22) = 3.98, p = .059, Figure 10A).  The 
reduced spinal-supraspinal communication in the acute phase of a contusion injury likely 
reduced reactivity to stimuli applied below the level of the lesion.  While contused 
animals were less reactive for the measure of below-level mechanical allodynia, 
however, they vocalized more than sham animals on the test of at-level pain, girdle 
reactivity (F (1, 21) = 6.93, p < .05, Figure 10B).  No other results approached 
significance (F’s < 1.2, p > .05).    
Morphine Administered.  As found in the previous study (Chapter III), the 
contused subjects administered significantly less morphine (1.5 mg/lever press) than 
sham subjects in the acute phase of injury. Contused animals self-administered only 8.4 
mg on average versus 21.1 mg in the sham group (Figure 11).  An ANOVA revealed a 
main effect of surgery (F (1, 10) = 15.43, p < .05). 
Rate of Administration.  In these experiments, we again examined how rapidly 
animals administered morphine (Figure 12).  The patterns seen here are nearly identical 
to those in the first experiment.  On Day 1, contused and sham rats diverge in the amount 
of morphine administered, and the amount of time spent pressing the lever.  Across days, 
contused rats maintain a moderate level of morphine administration, and administer 
morphine for eight hours (on Day 7).  The amount administered, and the rate at which it  
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Figure 10: Assessment of sensory reactivity prior to morphine administration.  Baseline 
tests of mechanical reactivity (A) and girdle reactivity (B) were conducted prior to 
morphine administration.  Contused animals were less reactive on motor tests of 
mechanical reactivity.  However, contused rats vocalized more in response to 
mechanical stimuli applied at and above the level of injury. * p < .05 
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Figure 11: The amount of morphine self-administered in the acute phase of 
SCI.  Contused animals administered significantly less morphine than sham 
animals when given access to a 1.5 mg per lever depression. * = p < .05 
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is administered suggests these rats are not administering for the hedonic properties of 
morphine. 
Locomotor Recovery.  As in the previous experiment, locomotor recovery was 
monitored for a 42-day period in both sham and contused subjects.  Again, sham 
controls received a maximum converted BBB score of 12 on the day following surgery, 
and this remained unchanged throughout the period of recovery in both vehicle and 
morphine groups. Subsequent analyses, therefore, focused on the recovery of the 
contused groups only. To investigate the effect of morphine administration on recovery 
of locomotor function, we separated the data into a period of administration (Days 1-7) 
and a period of recovery (Days 8-42).  As in the previous study (Chapter III), there was 
no significant effect of morphine administration on recovery of locomotor function at the 
dose administered (F’s < 1.0, p > .05).  Administering 10 mg/morphine per session or 
less, contused animals recovered to the same level of locomotor function as those 
administering saline (Figure 13). 
Weight.  As with locomotor recovery, weight data was separated into a period of 
administration (Days 1-7) and a period of recovery (Days 8-42).  During administration, 
contused and sham animals lost weight in both the 0.0 mg and 1.5 mg groups (Figure 14 
A & B).  Contused animals in the saline group lost more weight during this phase of 
injury.  These results are supported by a Day x Drug Condition interaction (F (6, 120) = 
2.81, p < .05).   
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Figure 13: Effects of morphine administration on recovery of locomotor 
function.  As in the previous experiment, a 1.5 mg concentration of morphine 
did not affect recovery of locomotor function when administration began in the 
acute phase of SCI (shaded area). 
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During the period of recovery (days 8-42), contused animals maintained a lower 
weight than sham animals in both the 0.0 mg and 1.5 mg groups (Figure 14 A & B).  
Morphine administration did not significantly increase this weight loss in the contused 
groups.  Weight loss in the sham animals was increased by morphine administration, but 
this effect did not persist throughout the recovery period.  There were significant main 
effects of drug condition (F (1, 20) = 6.66, p < .05) and surgery (F (1, 20) = 11.48, p < 
.05) on weight loss.  As can be seen in Figure 14, morphine treated animals lost more 
weight than saline controls, and the contusion produced greater weight loss than the 
sham injury.  In addition, there were significant Day x Drug Condition (F (11, 220) = 
7.66, p < .05), Day x Surgery (F (11, 220) = 7.94, p < .05), and Day x Drug Condition x 
Surgery (F (11, 220) = 6.99, p < .05) interactions.  Post hoc tests indicated a significant 
difference between sham animals administering morphine and sham animals 
administering saline (p < .05). 
Sensory Reactivity. The tests of girdle, tail flick and hindpaw reactivity were 
repeated 42-days after the contusion or sham injury.  At this time point, there was no 
effect of morphine administration on mechanical reactivity, thermal hyperalgesia, or 
girdle reactivity (All F’s < 3.84, p > .05).  However, a contusion injury significantly 
decreased tail flick latency, regardless of drug treatment (F (1, 1) = 8.65, p < .05, Figure 
15).  No other results approached significance (F’s < 4.1, p > .05). 
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Figure 14: Morphine administration induces weight loss.  Both contused and 
sham animals lost weight during the period of self-administration (shaded 
area).  Contused animals (B) lost more weight than sham animals (A).  While 
morphine administration did not increase weight loss during the period of 
administration, it significantly slowed regain of weight.  
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Figure 15: Tests of sensory reactivity after morphine administration.  42-
days following injury, contused animals showed a significantly decreased tail 
flick latency.  There was not a lasting effect of morphine administration.  * p 
< .05  
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Morphine Self-Administration is Not Decreased in the Chronic Phase of Injury 
In the acute phase of injury, we observed a decrease in morphine self-
administration in injured animals.  These animals, however, are not yet experiencing 
neuropathic pain.  The idea that neuropathic pain reduces the abuse liability of opioids 
has not been examined following a spinal cord injury.  Thus, we assessed the addictive 
potential of morphine in the chronic (after symptoms of neuropathic pain have 
developed) phase of SCI using a self-administration paradigm. 
 Sensory Reactivity.  In this group, baseline tests of sensory reactivity were 
conducted 14 days after injury, before morphine self-administration sessions began.  At 
this time, contused animals withdrew their hindlimbs to a lower force von Frey filament 
than sham animals, indicating these animals are showing signs of mechanical allodynia.  
There was a main effect of surgery on mechanical reactivity thresholds (F (1, 22) = 
13.84, p < .05, Figure 16).  There were no differences in vocalization to a mechanical 
stimulus, in thermal hyperalgesia, or in response to girdle stimulation (All F’s < 1.0, p > 
.05).   
Morphine Administered.  In contrast to the acute phase of injury, we found 
contused and sham animals took similar amounts of morphine when administration 
began 14-days following injury (F < 1.0, p > .05).  On average, injured animals self-
administered 25.61 mg / day while sham rats self-administered 19.86 mg / day (Figure 
17). 
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Figure 16: Tests of tactile reactivity prior to morphine 
administration. 14-days post surgery, contused animals were 
showing signs of mechanical allodynia when compared to 
sham controls. * p < .05 
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Figure 17: Morphine self-administration in the early chronic phase of 
SCI.  In this early chronic phase of injury, contused animals 
administered as much morphine as sham animals. 
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Rate of Administration.  In the early chronic phase of injury, the rate of 
administration in the contused rats is different than the acute phase.  On day 1 of 
administration, contused animals administered an amount of morphine commensurate 
with sham controls.  They administered around 20 mg of morphine in the first five hours 
of the self-administration session.  The amount they administered increased over days, 
and, by day 7, they were administering nearly the entire 30 mg.  This administration 
occurred over ten hours of the session.  While the amount they are administering is 
greatly increased, it is administered over a longer period of time (Figure 18).   
Locomotor Recovery.  In this experiment, the 42 days were separated into three 
periods: prior to morphine administration (Days 1-13), during morphine administration 
(Days 14-20), and during recovery (Days 21-42).  There was no effect of morphine on 
recovery of locomotor function in any of these periods (all F’s < 1.0, p > .05; Figure 19). 
Weight.  As with recovery of locomotor function, weight change was examined 
in three periods.  Prior to morphine administration (days 1-13), contused animals lost 
weight relative to sham controls (Figure 20 A & B).  This result is supported by a 
significant main effect of surgery (F (1, 20) = 54.75, p < .0001) and a Day x Surgery 
interaction (F (9, 180) = 13.39, p < .0001).   
During the period of morphine administration, contused rats continued to weigh 
less than sham animals and weight loss was increased by the administration of morphine.  
There was a significant main effect of surgery (F (1, 20) = 26.52, p < .0001), and a Day 
x Drug Condition interaction (F (1, 20) = 9.41, p < .01) for weight loss in this period.  As   
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Figure 19: Locomotor recovery is not affected by morphine 
administration in the chronic phase of SCI.  In this early chronic 
phase of injury, morphine administration, even at the high amount 
administered here, did not affect recovery of locomotor function. 
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Figure 20: Morphine administration leads to weight loss in the chronic phase 
of SCI.  Prior to morphine administration, contused animals (B) lost more 
weight than sham animals (A).  During the period of administration, contused 
animals continued to lose weight, and contused animals administering 
morphine weighed less than all other groups.  During the recovery period, all 
rats regained weight, but contused animals remained smaller.  In addition, 
contused rats administering morphine weighed less than those administering 
saline. 
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can be seen in Figure 20 A & B, contused rats administering morphine weighed 
significantly less than injured subjects treated with saline or sham subjects. 
During recovery (days 21-42), all rats began to regain weight, but contused rats 
remained smaller than their sham counterparts.  In addition, both contused and sham 
animals administering morphine weighed less than injured and sham animals 
administering saline.  Supporting these results, an ANOVA yielded a significant main 
effect of drug condition (F (1, 20) = 10.64, p < .01), and surgery (F (1, 20) = 16.99, p < 
.001), and a significant Day x Drug Condition interaction (F (6, 120) = 20.918, p < 
.0001).  As found previously, morphine administration increased weight loss as did the 
contusion, relative to sham, injury. Post hoc analyses indicated that contused animals 
administering morphine lost significantly more weight than the contused animals 
administering saline (p > .05), weighing only 4.86 grams more on Day 42 than on Day 1, 
versus 22.41 grams more in the saline group.  
Sensory Reactivity.  Forty-two days after injury, there was no lasting effect of 
morphine administration on measures of sensory reactivity (all F’s < 1, p > .05).  A 
contusion injury significantly increased vocalizations on the girdle test of at-level 
neuropathic pain (F (1, 1) = 5.75, p < .05, Figure 21).  No other results approached 
significance (all F’s < 1.1, p > .05). 
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Figure 21: Tests of neuropathic pain conducted after morphine 
administration. Forty-two days following injury, contused animals 
vocalized significantly more on a test of at-level girdle reactivity.  
There was no lasting effect of morphine treatment. * p < .05 
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Contused Rats Showing Established Neuropathic Pain do Not Self-Administer Less 
Morphine 
  The results for the early chronic phase are in contrast to those in the literature 
reporting a reduced addictive potential of morphine in peripheral injury models with  
neuropathic pain.  In the contusion model of SCI, symptoms of neuropathic pain 
typically begin to develop around 14 days post injury.  However, in our study, many of 
the animals were not showing signs of neuropathic pain at this early time point.  Thus, 
we extended the period of administration to begin 35 days after injury, when neuropathic 
pain is more established. Here, we examined only the amount of morphine administered 
in contused and sham animals given access to 1.5 mg of morphine and their sensory 
reactivity.  We did not monitor recovery in these animals. 
 Sensory Reactivity.  Baseline measures of sensory reactivity were recorded on 
day 35 following injury, before initiation of self-administration sessions.  In a test of 
mechanical allodynia, contused subjects were less reactive than sham animals (F (1, 10) 
= 7.65, p < .05), but were not different in vocalizations (F < 1.0, p > .05).  At this time, 
however, we found contused animals showed a shorter tail flick latency than sham 
animals, indicating the development of thermal hyperalgesia.  This result approached 
significance (F (1, 10) = 3.84, p = .07).  In addition, we found contused animals 
vocalized more in the girdle test than sham animals (an average of 10.2 vocalizations vs 
1.0, respectively) indicating the development of neuropathic pain.  This result, however, 
was not significant (F < 1.0, p > .05). 
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 As we were testing the effect of neuropathic pain on morphine self-
administration, the initial lack of statistical significance for measures of neuropathic pain 
was concerning.  In this model of injury, however, not all contused animals will develop 
neuropathic pain, and this can make groups too small to have power to yield statistical 
significance.  Thus, we separated contused animals into groups based on the girdle test, 
an indicator of the development of at-level neuropathic pain.  We found four of six 
animals were showing signs of neuropathic pain (Figure 22).    
Morphine Administered.  As in the early chronic phase, contused animals 
administered as much morphine (21.5 mg / day average) as sham controls (22.9 mg / day 
average), shown in Figure 23A.  An ANOVA showed there was not a difference 
between these two groups (F (1, 10) = 40.74, p < .05).    
The animals experiencing neuropathic pain did not self-administer a different 
amount of morphine than pain-free contused or sham animals, though the result did 
approach significance (F (1, 9) = 3.80, p = .08).  Sham animals administered an average 
of 22.89 mg morphine, pain-free contused animals self-administered an average of 25.29 
mg, and contused animals showing signs of neuropathic pain self-administered an 
average of 19.61 mg (Figure 23B).  Further supporting similar levels of morphine self-
administration in animals experiencing neuropathic pain, use of girdle reactivity as a 
covariate in examining the amount of morphine administered did not yield a significant 
result (F <1.0, p > .05). 
Rate of Administration.  As with the early chronic phase, animals in this phase of 
injury begin by administering approximately 25 mg of morphine in 6 hours on day 1  
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Figure 22: Most contused animals are experiencing pain prior 
to morphine administration.   Four of six contused animals were 
showing signs of neuropathic pain.  No sham animals showed 
similar signs of pain. 
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Figure 23: Amounts of morphine administered based on pain level.  In 
the late chronic phase of injury, contused animals administered as much 
morphine as sham animals (A).  When contused animals are separated 
into a pain-free group and a group experiencing pain, there was not a 
significant difference in the amount of morphine administered (B). 
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(Figure 24).  Rather than increasing the rate and amount administered over days, 
however, they remained consistent in the time they administered (6-7 hours). 
Discussion 
These data do not support the hypothesis that neuropathic pain lowers the 
addictive potential of morphine after SCI.  In contrast, the data reported here indicate 
that the decreased abuse liability observed in the acute phase of a contusion injury has 
receded by the chronic phase.  In the current studies, contused animals in the acute phase 
of injury self-administered significantly less morphine than their sham counterparts.  By 
the early chronic phase, however, when symptoms of neuropathic pain are just beginning 
to develop we found that contused animals self-administered as much morphine as sham 
animals.  In addition, contused animals in the chronic phase of injury, experiencing 
neuropathic pain, self-administered an amount of morphine commensurate with their 
pain-free counterparts and sham animals.  Our results demonstrate that the addictive 
potential of morphine varies depending on the phase of injury in which it is administered 
and neuropathic pain symptoms do not negate abuse liability in this model. 
In peripheral models of neuropathic pain, reports from the literature indicate that 
the presence of pain reduces the abuse liability of morphine.  The variation in results 
between our studies, using a central model of neuropathic pain, and peripheral models 
may stem from differences in experimental design (e.g. amount of morphine available, 
length of self-administration sessions), the amount of time from injury onset to initiation 
of self-administration sessions, and prior experience in self-administration chambers.  
For example, Martin et al. (2007) found dose-dependent decreases in morphine self-
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administered following a spinal nerve ligation.  Animals experiencing pain self-
administered less morphine at doses up to 180 µg/kg, but not at higher (up to 600 µg/kg) 
doses.  The doses used in their study, compared to ours (and those used clinically), are 
low: 0.18 mg/kg versus approximately 5 mg/kg in our 1.5 mg group.  Accordingly, 
higher doses of morphine would not lead to differential self-administration in contused 
versus sham animals. While lower doses were not investigated in the current study, it is 
possible that contused animals would self-administer significantly less morphine than 
sham controls at lower doses.  Indeed, in the acute phase of injury, we found contused 
animals self-administered significantly less of the 1.5 mg dose, compared with a 3.0 mg 
dose, but this difference did not persist into the chronic phase of injury.   
Our experimental design also differed in the length of the self-administration 
sessions.  In studies of cocaine self-administration, session length has been shown to be 
an important factor in determining both the rate (infusions/ hour) and amount of cocaine 
self-administered (Ahmed & Koob, 1998; Wee et al., 2007).  In a 1-hour session, rats 
maintained a low, stable rate of administration (Ahmed & Koob, 1998).  In a 12-hour 
session, however, more cocaine was self-administered, and was administered in a shorter 
amount of time (Wee et al., 2007).  The Martin et al. (2007) study used four, 1-hour 
sessions in which different doses of drug were available each hour.  In contrast, our 
studies have all used 12-hour sessions.  With a 12-hour session, it is anticipated that rats 
will self-administer more morphine more rapidly than would be seen in a 1-hour session.  
The 12-hour session, therefore, provides a good index of addictive behavior.  It is 
important to note that the 12-hour session also more closely resembles patient controlled 
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analgesia, making use of longer sessions clinically relevant in the study of addictive 
behavior. 
With the 12-hour session allowing for the assessment of addictive behavior, we 
found contused animals administering the 1.5 mg dose in the acute phase of injury did 
not develop addictive behaviors.  These contused animals maintained a low rate of 
morphine administration across the seven sessions.  This finding suggests that the acute, 
inflammatory pain these animals are experiencing is altering the rewarding properties of 
the drug. This change in abuse liability could result from several potential mechanisms. 
For example, a decrease in analgesic efficacy could reduce morphine self-administration.  
In the absence of rewarding analgesic effects, contused subjects given access to the 
1.5mg dose may not be motivated to continue administering the drug.  Supporting this, 
Martin et al., (2007) found that low doses of morphine (below 180 µg/kg) that did not 
reverse mechanical allodynia also did not support self-administration. Only doses that 
reversed mechanical allodynia maintained self-administration (Martin et al., 2007).  The 
analgesic efficacy of the 1.5 mg dose of morphine was not tested in the current study. 
Theoretically, however, a decreased analgesic efficacy, in our model, could result from 
increased glial activation.  Indeed, glial activation, characteristic of the acute phase of 
SCI, has been shown to counter morphine-induced analgesia (Mika, 2008).  Also 
characteristic of the acute phase of SCI are increases in spinal dynorphin.  As with glial 
activation, antinociceptive effects of morphine are decreased by elevations in spinal 
dynorphin (Malan et al., 2000).  Together, in the acute phase of SCI, increased glial 
activation and increased spinal dynorphin may act to decrease the rewarding, analgesic 
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properties of morphine.  Thus, low amounts of morphine are less rewarding and lead to 
decreased morphine self-administration in the acute phase of SCI.  Higher doses, 
however, appear to overcome these anti-analgesic effects.  This idea should be examined 
further in future studies.  
 In the chronic phase of injury, when neuropathic pain symptoms are displayed, 
many of the acute changes in glial activation and endogenous opioid activity have 
subsided. For example, a study by Adjan et al. (2007) found that dynorphin increases, 
following a T10 contusion injury in mice, is associated with the expression of caspase-3 
in greater than 90% of all neurons, oligodendrocytes, and astrocytes.  These increases 
were seen at 4 hours, but not 24-hours following SCI (Adjan et al., 2007).  Importantly, 
our morphine administration began approximately 24 hours after SCI.  Morphine 
administration, at this time, may prolong the elevation in dynorphin levels in this 
vulnerable phase of injury.  Similarly, following SCI astrocytes in the thoracic spinal 
dorsal horn are most activated from 24-hours to 7-days post injury, and microglia are 
most activated at 24-hours (Gwak et al., 2012). While glial activation continues for up to 
180 days following SCI (Gwak et al., 2012), and increases in pro-inflammatory 
cytokines are seen up to 28 days, the levels are not as high as in the acute phase of SCI. 
The reduced levels of glial activation and dynorphin may unmask the addictive potential 
of morphine in the chronic phase of SCI. 
Changes in the molecular milieu inherent to the acute and chronic phase of SCI 
may also explain the differential effects of morphine on locomotor recovery. In the 
previous experiment, self-administration of morphine at amounts greater than 50 
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mg/kg/day day significantly attenuated recovery of locomotor function when 
administration occurred from days 1-7 post SCI (Chapter III).  In the current 
experiments, animals in the acute phase of injury did not self-administer an amount over 
50 mg/kg/day, and did not show attenuated recovery of locomotor function.  This 
replicates our previous result at this dose (Chapter III).  However, contradicting these 
effects, we found contused animals administering over 50 mg/kg/day in the chronic 
phase of injury did not show attenuated recovery of locomotor function, compared to 
those administering saline. These data suggest that there are “windows of vulnerability” 
after SCI, in which morphine produces adverse effects on the recovery of locomotor 
function. It appears that morphine does not affect locomotor function after ‘spontaneous 
recovery’ has plateaued, as is typically seen in the rodent contusion model around 14 
days (Hook et al. 2004). 
In the previous chapter, we hypothesized that opioid administration may be 
compounding molecular changes characteristic of acute SCI to produce detrimental 
effects.  As discussed previously, by the chronic phase of injury, many of these 
molecular processes, including changes in endogenous opioid activity and glial 
activation, have stopped or are muted from the time immediately post injury.  Therefore, 
it is not expected that opioid administration, in the chronic phase of SCI, will have the 
same effects as in the acute phase of SCI.  For example, following SCI, there is an 
immediate increase in the levels of extracellular glutamate (McAdoo et al., 2005).  
Typically, these levels return to normal over the course of a couple hours (McAdoo et 
al., 2005), thus producing a short-lived effect on excitotoxicity and apoptosis.  Upon 
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further investigation, it was found that application of glutamate to the intact spinal cord, 
at levels reached following SCI, results in maximal apoptosis (of neurons and 
oligodendrocytes) 6 hours to 24 hours following application, with no additional 
apoptosis being seen from 3-28 days (Xu et al., 2008).  At an early time following 
injury, it is hypothesized that opioid administration contributes to increased levels of 
extracellular glutamate to prolong the period of excitotoxicity, and increase cell loss.  By 
the chronic phase of injury, however, there is unlikely to be a compounding effect of 
opioid administration because the endogenous levels of glutamate have returned to 
normal and apoptosis is no longer occurring.  Therefore, opioid administration would 
produce detrimental effects on recovery of locomotor function in the acute, but not the 
chronic phase of SCI. 
 In these experiments, we also saw weight loss occurring as a result of morphine 
administration.  Weight loss can occur as a result of withdrawal syndrome (Gu et al., 
2005), which may contribute the weight loss we observed in the early chronic phase of 
injury.  Indeed, the high amounts of morphine administered each day in the early chronic 
phase of injury led to signs of withdrawal (e.g. wet-dog shakes, teeth chewing) 
throughout the period of administration and into the recovery period, though these were 
not quantified.  Additionally, morphine administration has been shown to affect food 
intake (Nogueiras et al., 2012; Ferenczi et al., 2010).  As there were no effects on food 
consumption in the first experiments, we did not monitor food intake in this study.  
However, it is worth noting that an altered feeding pattern contributing to weight loss 
remains a possibility.   
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Despite these plausible explanations, we propose that the weight loss is not due 
solely to withdrawal or alterations in food/fluid consumption.  Hook et al. (2009; 2011) 
have shown that a single intrathecal administration of morphine produces lasting weight 
loss in rats.  This weight loss cannot result from withdrawal, and acute administration of 
morphine does not significantly affect food intake (Ferenczi et al., 2010).  This result 
suggests that opioid administration is causing a dysregulation in the acute phase of injury 
that contributes to these effects.  Supporting this notion further, the administration of 
high doses of morphine in the early chronic phase did not have as significant an impact 
on weight loss, nor as lasting an effect, as high doses of morphine administered in the 
acute phase of injury.  In the chronic phase, animals lost weight during morphine 
administration, but recovered to the same level as saline-treated rats, and gained more 
weight than sham controls.  In contrast, animals administering the high dose in the acute 
phase of injury lost significantly more weight, never recovered weight to the same level 
as saline-treated rats, and were far below sham animals.  These results suggest that there 
are complex interactions occurring with SCI and opioid administration that affect weight 
in a dose- and phase-dependent manner.  The root cause of this weight loss remains to be 
determined. 
 Overall, the data presented here suggest that the phase of injury critically affects 
the adverse outcomes associated with morphine administration.  Nonetheless, the use of 
morphine may be fraught with adverse consequences, irrespective of the time of use.  
We have shown that morphine administered in the acute, but not the chronic phase of 
injury attenuates recovery of locomotor function.  Based on these findings, use of opioid 
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analgesics, at high doses, should be avoided in the acute phase of injury.  In the chronic 
phase, however, even a moderate dose of morphine leads to addictive behavior in injured 
animals, suggesting that a state of neuropathic pain does not reduce the addictive 
potential of morphine.  Thus, the use of opioids analgesics should be closely monitored 
in this phase of injury.  As one of few effective analgesics available for the treatment of 
pain after SCI, it is difficult to suggest that morphine be removed as a potential treatment 
for the injured population.  Instead, future studies must focus on the molecular 
mechanisms underlying morphine administration, as well as the potential synergistic 
actions of opioids and SCI pathology (Woller & Hook, 2013), to negatively affect 
addiction, locomotor recovery, pain, and general health. 
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CHAPTER V 
RECEPTOR SYSTEMS CONTRIBUTING TO DECREASED RECOVERY OF 
LOCOMOTOR FUNCTION 
The experimental results described in the previous chapters suggest that changes 
occurring in the acute phase of SCI leave the spinal cord vulnerable to the adverse 
secondary consequences of morphine administration.  Specifically, morphine 
administration in the acute phase of injury leads to deficits in locomotor recovery that 
are not seen with administration in the chronic phase of SCI.  It has been suggested that 
changes in the dynorphin/KOR (kappa opioid receptor) system and increased glial 
activation contribute to hyperexcitability, and a loss of cells, which could underlie these 
deficits (Chapter I).  However, whether locomotor deficits associated with morphine 
administration result from activation of one (or both) of these systems has not been 
investigated.  In addition to these two systems, morphine is known to bind in a classic 
fashion to the MOR (mu opioid receptor), and in a non-classic manner to both TLR2 
(Toll-like receptor 2) and TLR4 (Toll-like receptor 4; for review see Hutchinson et al., 
2011).  The involvement of each receptor system in contributing to morphine-induced 
locomotor deficits following SCI has not been addressed. 
As with glial activation and the KOR system, there is evidence indicating that 
activation of TLRs may contribute to the detrimental effects of morphine administration.  
Morphine binds to both TLR2, found on neurons, and TLR4 located on microglia and 
activated astrocytes.  Upon activation, these receptors initiate pathways resulting in the 
release of the pro-inflammatory cytokine TNFα (Tumor necrosis factor α; Hutchinson, 
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2011; Papadopoulos et al., 2013; Ozinsky et al., 2000).  Increased release of TNFα has 
been associated with a variety of pathologies including the development of allodynia in 
inflammatory and peripheral-injury induced pain (Garraway et al., (submitted); Schäfers 
et al., 2003b; Zhang et al., 2011; Leung & Cahill, 2010).  In addition, TNFα enhances 
neuronal excitability (Chen et al., 2011) and increases trafficking of calcium-permeable 
AMPARs, an effect that can ultimately lead to cell death (Ferguson et al., 2008).   
Despite evidence indicating that engaging TNF receptors can lead to apoptosis 
via the caspase-3 pathway (Guadagno et al., 2013), there has been little work done 
linking activation of TLR2 or TLR4 to altered recovery of locomotor function after SCI.  
TLRs (except TLR3) signal through an adaptor protein, myeloid differentiation primary 
response gene 88 (MyD88; Kawai & Akira, 2007; Okun et al., 2009).  The MyD88-
dependent pathway leads to the activation of NF-κB and results in the production of pro-
inflammatory cytokines, such as TNFα (for review see Hutchinson et al., 2011).  A 
recent study by Yao et al. (2012) examined the effect of inhibiting the MyD88 pathway 
following compression SCI.  They found early (immediately after injury) treatment with 
a peptide inhibiting MyD88 signaling decreased levels of the pro-inflammatory 
cytokines TNFα and IL1-β.  This single treatment also reduced activation of caspase-3, 
resulting in fewer apoptotic cells, greater numbers of spared neurons in the proximity of 
the injured area, decreased lesion size, and improved recovery of locomotor function 
(Yao et al., 2012).  This study suggests that TLR signaling following SCI is contributing 
to secondary pathology.  Given these effects, it is possible that morphine-induced 
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activation of TLRs after SCI contributes further to secondary pathology, and 
significantly impairs recovery of locomotor function.   
The aim of this study, therefore, was to examine changes in these receptor 
systems occurring after injury and prolonged morphine administration.  Specifically, we 
used western blots to examine alterations in protein expression of KOR, MOR, TLR2, 
TLR4, TNFα, and caspase-3.  In addition, fast blue and cresyl violet analyses allowed us 
to examine the effects of morphine administration on spared gray matter, white matter, 
and overall lesion size. 
Method 
Rats were implanted with a jugular catheter, and five days later were given a 
moderate contusion or sham injury, as outlined in Chapter II.  In this study, the 
experimenter administered morphine intravenously beginning 24 hours after the 
contusion or sham injury.  Animals were given 5 mg morphine / infusion through the 
back mount attached to the jugular catheter (i.v.) for 7 days on the following schedule: 
10 mg (days 1 and 2), 20 mg (days 3 and 4), and 30 mg (days 5, 6, and 7).  Control 
animals received an equivalent number and volume of infusions of 0.9% saline. Sensory 
reactivity tests were conducted on days 1, 3, 5, and 7 prior to administration of drugs in 
the morning, and in the evening, approximately 30 minutes after the last infusion.  
Twenty-four hours after the last morphine infusion, animals were sacrificed and spinal 
tissue was collected for western blot and histology as outlined in the General Method 
section. 
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Results 
Development of Tolerance   
In the previous studies, we were unable to monitor the development of tolerance 
across the seven self-administration sessions because the time since the last infusion of 
morphine varied, as did the amount of morphine self-administered each day.  Here, rats 
were given experimenter-controlled escalating doses of morphine over the course of 
seven days, and we were able to monitor the development of tolerance by conducting 
tests of sensory reactivity in the evening, after the last dose of morphine had been 
administered.   
Morphine administration produced a robust analgesia when administered 24-
hours after a sham or contusion injury; all animals reached the maximum 8 second tail 
flick latency.  Animals given saline do not show a change from their morning tail flick 
latency (Figure 25).  An ANOVA revealed a significant main effect of drug condition (F 
(1, 32) = 28.45, p < .05).   
Examining motor responses, to a mechanical stimulus, made over the seven days 
of administration revealed significant main effects of surgery (F (1, 32) = 47.97, p < 
.0001), drug treatment (F (1, 32) = 82.81, p < .0001), and a Surgery x Drug interaction 
(F (1, 32) = 37.97, p < .0001).  In general, contused subjects only respond to higher force 
von Frey filaments.  As shown in Figure 26A, morphine treatment led to a significant 
decrease in tactile reactivity; contused animals reached the maximum filament force 
without withdrawing the hindlimb.  By days 5 and 7, however, sham animals no longer  
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Figure 25: Analgesic response to the first administration of morphine.  A 
change from baseline response to the first day of morphine administration is 
shown.  All animals treated with morphine showed an increase in tail flick 
latency, while those given saline showed no change. *  p < .05 
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Figure 26: The development of tolerance to morphine.  In measures of 
mechanical allodynia (A & B) and thermal hyperalgesia (C), there were signs of 
the development of tolerance.  On day 5, animals treated with morphine were no 
longer reaching the maximum response to a mechanical or thermal stimulus. 
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reached the maximum threshold, indicating the development of tolerance.  These 
changes across testing sessions, however, were not significant (F’s < 2, p > .05).  Similar 
changes were seen in vocal responses across testing sessions (Figure 26 B).  In general, 
contused animals were less reactive than sham controls (F (1, 32) = 8.7, p < .05).  Again, 
morphine treatment significantly increased response threshold (F (1, 32) = 4.90, p < .05).  
By day 7, sham animals began vocalizing in response to mechanical stimulation, but this 
was not seen in contused animals. These results, across testing sessions, were not 
significant (F’s < 1, p > .05). 
 Measuring thermal hyperalgesia, there was a main effect of morphine treatment 
(F (1, 32) = 156.53, p < .0001).  Animals treated with morphine showed increased tail 
flick latencies.  However, this effect waned across days, indicating the development of 
morphine-induced tolerance.  By day 7, sham and contused rats, while still showing 
increased tail flick latencies relative to vehicle-treated controls, no longer reached the 
maximum tail flick latency of 8 seconds.  This is despite treatment with 30 mg (an 
amount approximately equal to100 mg/kg) of morphine.  An ANOVA showed an effect 
of day of treatment (F (3, 32) = 3.54, p < .05), but no interactions were significant (F’s < 
3.0, p > .05). 
Development of Opioid-Induced Hyperalgesia   
In previous experiments, we had not been able to assess the development of 
opioid-induced hyperalgesia because of the varying amounts of morphine administered 
across self-administration sessions.  Opioid-induced hyperalgesia (OIH) is a 
phenomenon in which the repeated administration of morphine leads to the development 
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of pain, either mechanical or thermal.  By assessing sensory reactivity in the morning, 
before any morphine administration began, we were able to monitor the development of 
OIH in these animals.   
The development of OIH was first assessed by examining withdrawal of the 
hindlimb to a von Frey filament.  Again, contused animals tend to be less reactive on this 
test, and this was confirmed by a significant main effect of surgery (F (1, 32) = 38.54, p 
<  .05).  Over days of testing, sham and contused animals treated with morphine became 
much more reactive and began withdrawing their hindlimb at lower forces.  Sham 
animals treated with morphine, by day 7, were more reactive than sham animals treated 
with saline.  These results indicate morphine treatment is leading to the development of 
pain (OIH).  An ANOVA confirmed these results showing a significant effect of day of 
testing (F (3, 96) = 23.73, p < .05), and Day x Drug (F (3, 96) = 5.93, p < .05) and Day x 
Surgery x Drug (F (3, 96) = 5.48, p < .05) interactions. 
 Vocalizations in response to tactile stimulation showed a similar, though more 
dramatic, effect.  Contused animals are less reactive than sham animals, in general (F (1, 
32) = 12.61, p < .05).  Morphine treatment led to a significant decrease in threshold 
required to elicit a response (F (1, 32) = 9.68, p < .05), and this effect was greatest in the 
sham animals (F (1, 32) = 4.40, p < .05).  Over days, animals treated with morphine 
showed the development of OIH.  This was supported by a significant Day x Drug 
interaction (F (3, 96) = 6.89, p < .05).   
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Figure 27: The development of opioid-induced hyperalgesia. Animals were 
tested in the morning, prior to any morphine treatment.  Over days of testing, 
animals being treated with morphine showed increased reactivity (withdrawal 
of the hindlimb and vocalization) to mechanical stimuli.  The effect was most 
pronounced in sham animals. 
  102 
Using the tail flick test to measure thermal hyperalgesia (Figure 27C), contused animals 
exhibited a faster tail flick than sham animals (F (1, 32) = 5.05, p < .05). All animals 
exhibited similar tail flick latencies regardless of prior treatment with morphine.  There 
was no evidence for the development of opioid-induced hyperalgesia on this measure. 
Locomotor Recovery   
As in previous experiments, we assessed recovery of locomotor function using 
the BBB scale.  Previously, in the acute phase of injury, we found a high amount of 
morphine administration significantly attenuated recovery of locomotor function, but a 
low dose did not.  In this experiment, all animals were given an average of 21.4 mg each 
day.  This corresponds to approximately 70-74 mg/kg/day in these rats, an amount that, 
based on previous results, should attenuate functional recovery.  As expected, contused 
rats treated with morphine recovered significantly less function over the first week than 
contused animals treated with saline, despite having equal converted BBB scores on day 
1 (1.6 in the morphine group and 1.8 in the vehicle).  This result is supported by an 
ANCOVA showing Day x Drug Condition interaction (F (5, 75) = 5.27, p < .05).  
Contused animals treated with morphine recovered to an average converted BBB score 
of 4.8, while those treated with saline recovered to a 7.1, in the first seven days (Figure 
28). 
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Figure 28: Locomotor recovery following morphine administration.  Contused 
subjects treated with high amounts of morphine recovered significantly less 
locomotor function over the first week than did animals treated with saline. *  p < 
.05 
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Figure 29: Weight loss occurring during morphine administration.  Sham animals 
(A) treated with morphine lost significantly more weight during the seven days of 
administration than sham animals treated with vehicle.  In contrast, all contused 
(B) animals lost weight throughout the seven days, and this was not affected 
further by morphine administration.  *  p < .05 
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Weight   
In previous experiments, we have shown morphine administration leads to a 
significant weight loss.  Here, we found sham rats given morphine lost weight over the 
first week (Figure 29A), while those given saline did not.  As found previously  
 (Chapter IV), contused rats lost weight in the first week of injury irrespective of drug 
treatment (Figure 29B).  This weight loss, characteristic of a contusion injury, likely 
masked additional effects of morphine in the truncated assessment period. Nonetheless, 
there was a main effect of surgery (F (1, 32) = 24.18, p < .05), a Day x Surgery (F (6, 
192) = 9.88, p < .05), Day x Drug Condition (F (6, 192) = 6.59, p < .05), and a Day x 
Surgery x Drug Condition (F (6, 192) = 2.57, p < .05) interaction.  Post hoc analyses 
indicated that sham animals treated with morphine weighed significantly less than sham 
animals treated with vehicle. 
Histology   
Following morphine administration, we examined the effect of contusion injury 
and morphine administration on spinal tissue.  Tissue was analyzed as three regions 
within the same 1-cm section.  Rostral tissue was defined as -2400, -1800, and -1200 µm 
from the impacted region.  Center tissue was defined as -600, 0, and 600 µm, and caudal 
was 1200, 1800, and 2400 µm from the impacted region (Figure 30).   
We found that a contusion injury significantly decreased the amount of gray 
matter at the site of injury (center), as well as rostral and caudal to the injury site (Figure 
31A) relative to sham subjects.  These results are supported by an ANOVA showing a 
significant main effect of surgery condition (center: F (1, 8) = 17.05, p < .05; rostral: F  
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Figure 30: Spinal sections for histology.  The nine sections used for analyses are depicted.  
The first three sections were considered the area rostral to injury, the next three contained the 
lesion center, and the last three were caudal to the injury.  In this sham vehicle subject, gray 
matter is outlined in pink and white matter in green. 
  107 
  
Figure 31: Analysis of tissue.  The percentage of gray matter (A) was significantly 
reduced by contusion injury at all regions of the spinal cord, but white matter was not 
changed (B). Overall, a contusion injury increased the amount of damage to the spinal 
cord (C).  The amount of missing tissue (D) was not different across surgery 
conditions.  Damage was increased by morphine administration at the center of the 
spinal cord in contused animals. * p < .05, #, significant group difference. 
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(1, 8) = 28.50, p < .05; caudal: F (1, 8) = 7.00, p < .05).  There was not a main effect of 
drug treatment (F’s < 3.81, p > .05).  In the area rostral to the injury center, there were 
significant Distance x Surgery (F (2, 16) = 5.64, p < .05) and Distance x Drug 
interactions (F (2, 16) = 6.89, p < .05) indicating that the amount of gray tissue 
remaining varied depending on the spatial location in the cord.  The area closest to the 
lesion center had the least gray tissue remaining, and there was significantly less gray 
matter in morphine-treated animals.  At the center of the lesion and the area caudal, no 
other results approached significance (F’s < 3.37, p > .05).   
As shown in Figure 31B, at seven days post injury, there was no effect of 
contusion injury or morphine administration on the percentage of white matter spared 
(all F’s (rostral, center, and caudal) < 2.90, p’s > .05).  This is expected as cell loss and 
cavitation progress from the gray matter outward toward the white matter with time, 
eventually leaving just a rim of spared white matter (James et al., 2011).   
When examining the percentage of lesioned tissue, we found a contusion injury 
significantly increased lesion area in the rostral, center, and caudal regions of the spinal 
cord (Figure 31C; rostral: (F (1, 8) = 6.66, p < .05; center: F (1, 8) = 22.85, p < .05; 
caudal: F (1, 8) = 13.18, p < .05).  Morphine administration further increased the 
percentage of damage in the center area of the spinal cord in contused animals.  An 
ANOVA revealed a significant main effect of drug condition (F (1, 8) = 7.66, p < .05).  
Also at the center of the lesion, there were significant Surgery x Drug (F (1, 8) = 7.80, p 
< .05) and Distance x Surgery interactions (F (2, 16) = 3.84, p < .05).   Morphine  
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Figure 32: Morphine treatment increases lesion size at the center of the cord.  
Contused vehicle animals (A) show lesion area (the red outline; B), but this is 
increased in contused animals treated with morphine (C & D).  Black = outline of 
white matter. Blue = outline of normal gray matter.  Red= outline of lesion area. 
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treatment increased the percentage of lesion area in contused animals only, and had the 
most impact in the area closest to the center of the injury (Figure 32).  
In previous experiments (Hook et al., 2011; Grau et al., 2004), the amount of 
missing tissue was also assessed.  Missing tissue accounts for tissue lost as a result of 
factors such as atrophy, necrosis, or apoptosis that are not accounted for in analyses of 
lesion area alone (see Hook et al., 2011).  As shown in Figure 31D at this early time  
point, we did not see a significant amount of missing tissue in any of the groups (all F’s 
< 4.86, p’s > .05). 
Western Blot   
At the time of tissue collection, cords were hemisected to allow for the 
examination of dorsal-ventral changes in protein expression.  With these sections, we 
compared changes in each half individually, the changes in dorsal versus ventral, and 
changes in an average “overall” cord.  Analyses of changes in the dorsal versus ventral 
portion of the spinal cord were conducted to examine whether protein levels were 
differentially expressed in the two halves (a within subjects variable). Specifically, 
changes in protein expression for the MOR, KOR, TLR2, TLR4, TNFα, and caspase-3 
were assessed.   
We used β-Actin as a control protein, and analyzed protein expression levels for 
differences.  In these samples, there were no significant differences in β-actin expression 
in the ventral portions (Mini: F’s < 1.0, p > .05; Criterion:  F’s < 1.5, p > .05).  In the 
dorsal portions, there was a significant effect of surgery on the Mini gels (F (1, 19) = 
7.968, p < .05) and a significant Surgery x Drug interaction (F (1, 19) = 8.51, p < .05).  
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Also in the dorsal portions on the Criterion gels, there was a significant Surgery x Drug 
interaction (F (1, 19) = 4.60, p < .05).  Future analyses will include tubulin as an 
endogenous control.  However, for these analyses, we used β-actin despite the 
differences. 
Effects of Repeated Morphine Administration and Contusion Injury on MOR and KOR 
Protein Expression 
In examining protein expression levels in the dorsal portion of the spinal cord 
(Figure 33 A & B), we found increased MOR protein in the sham animals treated with 
morphine, but decreased MOR protein in contused animals treated with morphine.  The 
contused animals treated with saline showed no change.  There were, however, no 
significant differences (F’s < 2.97, p > .05).  The change in MOR protein levels on the 
ventral half were similar to the dorsal, but sham animals treated with morphine did not 
show as much of an increase.  No results approached significance (F’s < 1.20, p > .05).  
Comparing the dorsal and ventral halves, there was a divergent effect of 
morphine treatment on sham and contused animals: contused animals treated with 
morphine showed decreased MOR protein levels while sham animals treated with 
morphine showed increased MOR protein levels.  Contused animals treated with saline 
showed no difference from sham animals treated with saline.  These results were, 
however, not significant (F’s < 3.23, p’s > .05).  Averaging the two halves into an 
“overall” cord also yielded no significant results (F’s < 2.63, p > .05). 
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Figure 33: MOR and KOR protein levels.  There are no significant differences in MOR 
(A & B) or KOR (C & D) protein levels in the dorsal, ventral, or overall cord.  CV = 
contused vehicle, CM = contused morphine, SV = sham vehicle, SM = sham morphine. 
  113 
Levels of KOR protein, Figure 33 C & D, were not changed by either surgery 
condition or drug treatment in the dorsal portion of the spinal cord (F’s < 1.2, p > .05).  
Contused subjects treated with morphine, however, appeared to have lower levels of 
KOR protein than the other three groups.  In the ventral portion of the spinal cord, there 
were, again, no differences in KOR protein levels (F’s < 1.0, p > .05).  Comparing the 
dorsal and ventral halves of the cord, there were no changes in KOR protein levels (F’s < 
2.0, p > .05).  Nor were there changes when looking at the “overall” cord.  Here, KOR 
protein levels seemed equal between groups (F’s < 1.0, p > .05). 
Effects of Repeated Morphine Administration and Contusion Injury on TLR2 and TLR4 
Protein Expression 
 In examining changes in TLR2 protein levels in the dorsal portion of the spinal 
cord (Figure 34 A & B), we saw a decrease in contused animals treated with morphine.  
All other groups were at the same level as sham animals treated with saline.  These  
differences were not significant (F’s < 1.50, p > .05).  On the ventral portion of the 
spinal cord, there were no changes in TLR2 protein levels (F’s < 1, p >  .05).   
 Comparing the dorsal half to the ventral half of the cord, there seemed to be a 
slight decrease in TLR2 protein in contused subjects treated with morphine, but this was 
not significant nor were there any other significant differences (F’s < 1.5, p > .05).  
These results are also reflected in the analysis of the “overall” cord (F’s <1, p > .05). 
 In the dorsal portion of the spinal cord, there were no significant differences in 
TLR4 protein as a result of surgery condition or morphine treatment (F’s < 2.00, p >  
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Figure 34: TLR2 and TLR4 protein levels in the spinal cord.  There were no changes 
in TLR2 (A & B) and TLR4 (C & D) protein expression in the dorsal and ventral 
portions of the spinal cord.  CV = contused vehicle, CM = contused morphine, SV= 
sham vehicle, SM = sham morphine. 
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.05).  Again, though, there appeared to be divergent effects of morphine treatment on 
contused versus sham subjects (Figure 34 C & D), and no change in the subjects treated 
with saline.  TLR4 protein levels were quite different in the ventral portion of the spinal 
cord.  In this portion, morphine treatment had no effect relative to saline animals treated 
with saline.  Contused animals treated with saline, however, had increased TLR4 protein 
levels.  These results were not significant (F’s < 4.00, p > .05). 
 Comparing the dorsal portion of the cord to the ventral, there was a significant 
Surgery x Drug interaction stemming from the results described above (F (1, 17) = 4.56, 
p < .05).  No other differences approached significance (F’s < 3.00, p > .05).  Similarly, 
there were no differences in TLR4 protein expression when looking at the “overall” cord 
(F’s < 1.50, p > .05).  
Effects of Repeated Morphine Administration and Contusion Injury on TNFα Protein 
Expression 
 In the dorsal portion of the spinal cord, protein levels of TNFα (Figure 35 A & 
B) in contused rats treated with morphine appeared to drop to almost nothing.  There 
were no changes in TNFα in the other three groups.  No differences were significant (F’s 
< 1.5, p > .05).  In the ventral potion of the cord, all groups seemed to have decreased 
TNFα protein levels relative to sham animals treated with saline, but these differences 
were not significant (F’s < 2.0, p > .05).  There was a similar lack of significance when 
comparing the dorsal and ventral sections (F’s < 2.0, p > .05), and when looking at the 
“overall” cord (F’s < 1.5, p > .05). 
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Figure 35: Protein levels of TNFα in the spinal cord.  Following prolonged treatment with 
morphine, there are no changes in TNFα protein in either portion of the cord, or overall.  
Protein levels were also unchanged by surgery (A & B). CV = contused vehicle, CM = 
contused morphine, SV = sham vehicle, SM = sham morphine 
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Effects of Repeated Morphine Administration and Contusion Injury on Caspase-3 
Protein Expression 
 Caspase-3 presents as several bands between ~17 kDa and ~35 kDa, and we 
analyzed the band at approximately 35kDA, which represents the cleaved caspase 
product. There were no significant differences in caspase-3 protein in the dorsal portion 
of the spinal cord (Figure 36 A & B; p > .05) or in the ventral portion (p > .05).  
Changes in Protein Expression 24-hours After i.t. Morphine Administration 
Although there were no significant differences in protein expression for the 
morphine and saline-treated animals, there were trends for divergent expression across 
groups. Moreover, functionally we found significant effects on locomotor recovery, 
weight loss, and behavioral changes indicating the development of tolerance and opioid-
induced hyperalgesia. We hypothesized that, in only examining protein levels 24-hours 
after cessation of morphine administration, and 8-days after contusion injury, we missed 
the window of significant changes occurring at an earlier time (i.e. on Day 1 of morphine 
administration).  To test this, we examined changes in protein expression 24-hours 
following the administration of i.t. morphine (48-hours after contusion injury), which 
has also been shown to result in attenuated recovery of locomotor function and weight 
loss (Hook et al., 2009; 2011). 
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Figure 36: Protein levels of caspase-3 in the spinal cord.  Caspase-3 protein was 
neither changed by spinal cord injury nor morphine administration (A & B).  CV = 
contused vehicle, CM = contused morphine, SV = sham vehicle, SM = sham morphine 
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 Method 
An additional 21 animals (n=7) were used to examine the effects of acute i.t. 
morphine administration on changes in protein expression.  These animals were given a 
contusion (n=14) or sham injury (n=7) injury and a PE 10 catheter was implanted with 
the tip positioned 2 cm caudal to the lesion center.  Twenty-four hours after injury, 
subjects were given an intrathecal injection of 90 µg morphine or vehicle.  The next day 
animals were deeply anesthetized and a 1 cm section of the spinal cord was collected and 
immediately frozen in liquid nitrogen, as described in the General Methods (Chapter II).  
Spinal cords in this experiment were not cut into dorsal and ventral portions because 
there were no significant differences in the first experiment.  In addition, we wanted to 
focus on the changes induced by spinal cord injury and whether morphine administration 
caused further changes in contused animals treated with morphine.  Thus, we did not 
include a sham group treated with morphine. 
Results 
 Here, we again examined β-Actin levels for differences between groups.  In these 
experiments, there were no significant differences in the levels of β-Actin on the mini or 
criterion gels (F’s < 2.5, p > .05). 
Effects of Acute Morphine Administration and Contusion Injury on MOR and KOR 
Protein Expression 
 Similar to the changes seen with the repeated i.v. administration of morphine, we 
found protein levels of the MOR were significantly decreased by a contusion injury (F 
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(1, 18) = 11.12, p < .05; Figure 37 A & B).  This result is consistent with those seen after 
a peripheral nerve injury (Lee et al., 2011).  Protein levels were not further affected by 
morphine administration (F < 1.0, p > .05). 
 As shown in Figure 37 C & D, there were no changes in protein expression levels 
of the KOR 24-hours following intrathecal morphine administration (48-hours following 
a contusion injury).  All groups exhibited similar levels of KOR protein (F’s < 1.0, p’s > 
.05). 
Effects of Acute Morphine Administration and Contusion Injury on TLR2 and TLR4 
Protein Expression 
 Examining the protein levels of TLR2 failed to reveal a significant effect of 
contusion injury or morphine treatment (F’s < 3.26, p’s > .05, Figure 38 A & B).  
However, morphine treatment appears to decrease TLR2 protein levels, and this result 
trended toward significance (p = 0.09).  The changes seen following a single 
administration of morphine are comparable to those seen with repeated i.v. 
administration of morphine where treatment, in the contused subjects, appeared to 
slightly decrease TLR2 protein levels. 
 As seen in Figure 36 C & D, acute, i.t. treatment with morphine did not have an 
effect on TLR4 protein levels (F < 1.0, p > .05), but TLR4 protein levels were 
significantly increased in subjects with a contusion injury (F (1, 18) = 7.54, p < .05).  
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Figure 37: Protein levels of MOR and KOR in the spinal cord following i.t. 
morphine administration.  A contusion injury significantly decreased KOR protein 
in the spinal cord (A & B).  There were no differences in spinal KOR protein.  * p 
< .05, CV = contused vehicle, CM = contused morphine, SV = sham vehicle. 
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Effects of Acute Morphine Administration and Contusion Injury on TNFα Protein 
Expression 
 Twenty-four hour following the intrathecal administration of morphine, there 
were no changes in TNFα protein levels as a result of morphine administration (F< 1.0, p 
> .05) or contusion injury (F < 2.0, p > .05; Figure 39). 
Effects of Acute Morphine Administration and Contusion Injury on Caspase-3 Protein 
Expression 
 Again, we analyzed the cleaved caspase-3 product.  Here, we found caspase-3 is 
increased in contused animals relative to sham controls (Kruskall Wallis test, p < .05), 
but this is not further affected by morphine administration (Mann-Whitney U, p > .05; 
Figure 40).   
Discussion 
 In this experiment, we used behavioral, histological, and molecular methods to 
examine the effects of morphine administration following a contusion injury.  Animals 
were treated with high quantities of intravenous morphine for seven days, mimicking the 
pattern of the self-administration seen in Chapter III.  We found that prolonged treatment 
with morphine led to the development of tolerance beginning on day 5 of treatment.  On 
the test of mechanical allodynia, contused rats only showed slight signs of tolerance 
developing on day 7 of administration.  On the tail flick test of thermal reactivity, 
however, a reduction in the analgesic efficacy of morphine was evident in both sham and 
contused rats on Day 5 of administration. Together, these behavioral data indicate that 
animals are becoming tolerant to morphine.  The data also suggest that hyperalgesia 
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develops with chronic administration of morphine. Opioid induced hyperalgesia was 
particularly evident in the sham rats, but also clear following a contusion, on the 
measure of tactile reactivity. Overall, these data suggest that the increases in morphine 
administration, seen in the acute phase of a contusion injury may be due, in part, to the 
development of tolerance and opioid induced hyperalgesia. 
While the behavioral effects of repeated opioid administration on hyperalgesia 
and tolerance are clear, the molecular changes that might mediate these effects are not. 
In the literature, tolerance has been linked to activation of TLR4 (Hutchinson et al., 
2011).  Through activation of TLR4, IL-1β is released and has been shown to oppose the 
analgesic properties of morphine (Hutchinson et al., 2011).  In these experiments, 
however, we did not see a change in spinal expression of TLR4 protein after 7 days of 
tolerance-inducing morphine treatment.  On the basis of these data, we could suggest 
that TLR4 is not mediating tolerance in the SCI model. Indeed, others have shown that 
morphine-induced tolerance is not mediated solely by TLR4 activation (Fukagawa, 
2013).  Alternatively, activation of TLR4 may lead to increased pro-inflammatory 
cytokine expression after SCI, without changes in receptor expression level, and thereby 
mediate tolerance.  Indeed, Hook et al. (2011) found that IL-1 β levels are increased 
within 30 minutes of intrathecal morphine administration, relative to vehicle-treated SCI 
controls. Further, Hook et al. (2011) demonstrated that treatment with an IL-1 receptor 
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Figure 38: Spinal TLR2 and TLR4 protein levels following i.t. morphine 
administration.  There were no changes in spinal TLR 2 protein expression (A & B).  
Spinal levels of TLR4 were increased by a contusion injury (C & D).  *  p < .05, CV = 
contused vehicle, CM = contused morphine, SV = sham vehicle. 
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Figure 39: Protein expression of TNFα in the spinal cord.  There 
were no changes in spinal levels of TNFα following a contusion 
injury or morphine administration. CV = contused vehicle, CM = 
contused morphine, SV = sham vehicle 
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Figure 40: Protein levels of caspase-3 in the spinal cord. There was a 
significant increase in spinal levels of caspase-3 following a contusion 
injury.  CV = contused vehicle, CM = contused morphine, SV = sham 
vehicle. * p < .05 
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antagonist not only blocked the morphine-induced attenuation of locomotor recovery, 
but also prevented increases in at-level neuropathic pain symptoms that were potentiated 
by morphine administration. Future investigation of the temporal expression of pro-
inflammatory cytokines is warranted with respect to tolerance, as well as hyperalgesia. 
Moreover while the data presented here do not explain the molecular mechanisms 
underlying tolerance/hyperalgesia, it does provide insight into the reduced analgesic 
efficacy of morphine that was noted in these earlier studies (Hook et al. 2007; Hook et 
al., 2009).  For example, following acute SCI 30 µg of intrathecal morphine, a dose 
providing robust analgesia in sham-operated rats, is ineffective in providing complete 
analgesia (Hook et al., 2009). This could result from a decrease in spinal MOR.  Indeed, 
we found that a contusion injury significantly decreased MOR protein 48-hours 
following SCI.  There were no changes 8-days following SCI.  Similarly, Lee et al. 
(2011) examined MOR expression following spinal nerve injury and found injury down-
regulated MOR mRNA and protein in the DRG, and decreased protein expression in the 
spinal cord.  Interestingly, they also found decreased MOR protein at L4 (an uninjured 
area) 7 days after injury, but not 14-days following injury.  Decreases in receptor 
number can contribute to reduced analgesic efficacy.  Together, these results suggest a 
spatial localization of MOR protein expression following injury, but a highly variable 
temporal expression.  This result demonstrates the need to examine MOR protein at 
multiple time points following injury to better understand analgesic efficacy. 
Opioid-induced hyperalgesia is a phenomenon in which continuous 
administration of morphine leads, paradoxically, to the development of increased pain 
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sensitivity.  We saw behavioral signs of OIH developing in our animals, but the 
mechanisms underlying the development of OIH are less clear.  Mechanisms underlying 
OIH are thought to be similar to those underlying the development of neuropathic pain, 
with glial cells playing a critical role.  As it has been implicated in the development of 
pain, excitotoxicity occurring via activation of the KOR system is thought to be involved 
in the development of OIH.  In the current experiments, we failed to detect a significant 
change in KOR protein following SCI or morphine administration.  This is not entirely 
unexpected as many reports suggest increased levels of dynorphin lead to increased 
activation of the KOR, but not necessarily increases in KOR expression (Faden, 1990; 
Faden et al., 1985; Abraham et al., 2001).  Thus, the levels of KOR protein expression 
may remain stable, while activation in this system is increased.  This needs to be further 
explored. 
In addition to tolerance and hyperalgesia, we also found that chronic morphine 
exposure, as found for i.t. morphine (Hook et al., 2009; 2011), increased lesion size at 
the injury center. Morphine administration did not have effects rostral or caudal to the 
injury center, but the increased cell loss at the lesion center resulted, behaviorally, in 
decreased recovery of locomotor function.  Morphine treatment can initiate loss of cells 
through binding at classic and non-classic receptors.  Accordingly, neurons express 
TLR2, and, upon activation by ligands such as morphine, initiate pro-apoptotic signaling 
(Yao et al., 2012; Li et al., 2009).  In the current studies, however, we failed to find 
significant changes in TLR2 but did find significantly increased caspase-3 protein 48-
hours following a contusion injury.  While this is in contrast to studies of spinal cord 
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injury, which show increased levels of TLR2 for 14-days following SCI (Kigerl and 
Popovich, 2007), the result corresponds to increased caspase-3 activity seen after injury 
(Lu et al., 2013; Yao et al., 2012).  Additionally, our results contradict those examining 
changes in TLR2 expression following chronic morphine administration.  For example, 
Li et al. (2010) showed chronic morphine treatment increased both TLR2 mRNA and 
protein in neuronal cultures following 4 days of morphine treatment.  They also found 6 
days of morphine treatment increased caspase-3 levels, but TLR2 deficient neurons were 
not susceptible to this apoptosis (Li et al., 2010).  Importantly, many of these studies on 
TLR2 are conducted in vitro and the interaction of opioid administration with SCI has 
not been investigated.  As TLR2 receptor are predominantly located on neurons, it is 
possible that increased neuronal apoptosis is contributing to the lower levels of TLR2 
protein.  This issue can be examined further with immunohistochemistry. 
As with TLR2, TLR4 binds morphine in a non-classic fashion.  While TLR2 is 
predominantly located on neurons, TLR4 is found on microglia and activated astrocytes 
(see Hutchinson et al., 2011).  Therefore, morphine binding to TLR4 would not cause 
the direct apoptosis of neurons, but, via signaling cascades, could contribute to cell loss.  
As mentioned previously, TLR4 signals through one of two adaptor proteins: MyD88 or 
Toll/IL-1 receptor domain-containing adapter-inducing interferon-β (TRIF; see 
Hutchinson et al., 2011).  Through the MyD88 adaptor protein, TLR4 signaling activates 
NF-κB and results in the production of pro-inflammatory cytokines (e.g. IL-1β and 
TNFα), and can lead to the activation of caspase-3.  Indeed, these pathways are activated 
following SCI (Yao et al., 2012), and a spinal cord injury significantly increases TLR4 
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mRNA from 3-7 days (Kigerl & Popovich, 2007).  Consistent with this data, 8 days 
following SCI, we did not see changes in TLR4 protein.  However, there was a 
significant increase in TLR4 protein 48-hours following a contusion injury, suggesting 
TLR4 activation may contribute to cell loss, via increased release of pro-inflammatory 
cytokines in the early acute phase of SCI.  This effect does not appear to be mediated 
through TNFα as we failed to find significant changes in protein 48-hours or 8-days 
following contusion injury, but may be mediated through other pro-inflammatory 
cytokines, such as IL-1B (Hook et al., 2011). 
Together, these studies demonstrate the need to further investigate the effects of 
morphine following SCI.  At the times examined, we found very few significant 
changes.  However, the literature suggests that expression of various proteins fluctuates 
with time post injury and morphine administration.  In addition, the dose of morphine 
administered seems to play a key role in initiating pro-inflammatory pathways.  We 
chose our experimental treatment (7 days of administration of high quantities of 
morphine) because high amounts of intravenous morphine had been shown to produce 
detrimental effects, while lower doses did not.  The data shown here, replicated these 
behavioral results, but failed to find significant changes in protein expression. We 
hypothesize that morphine may be having the greatest impact in a more acute phase of 
SCI (Days 1-2), and that changes in protein expression may be more apparent at time 
points closer to drug administration (i.e. 3 hours after administration).  Future studies 
should examine earlier time points following SCI and morphine administration, and use 
multiple methods (e.g. immunohistochemistry, PCR) to assess changes. 
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CHAPTER VI2 
 
GENERAL DISCUSSION AND CONCLUSIONS 
The experiments in this dissertation examined the abuse liability of morphine in 
the acute (Chapter III) and chronic (Chapter IV) phases of SCI.  We found a reduced 
addictive potential of morphine at a moderate dose in the acute, but not the chronic 
phase of injury.  In addition, we examined the impact of morphine administration on 
recovery of locomotor function and the development of pain (Chapters III and IV).  We 
found morphine administration significantly undermined recovery of locomotor function 
in the acute, but not the chronic phase of injury.  After the cessation of morphine 
administration, we did not find an affect of administration on long-term pain reactivity.  
These results indicate that molecular processes occurring in the acute phase of injury as 
a result of the contusion injury seem to be “protecting” the animal from addiction, but 
contributing to decreased recovery of locomotor function. Finally, we examined the 
receptor systems that may underlie the detrimental effects of morphine on recovery of 
locomotor function (Chapter V).  In the introduction, it was hypothesized that opioid 
administration following SCI could potentiate excitotoxic cell death (via increased 
dynorphin levels and glutamate dysregulation), and increase glial activation resulting in 
increased release of pro-inflammatory cytokines.  Indeed, increased activation of the 
KOR and increased levels of pro-inflammatory cytokines have been associated with 
reduced analgesic efficacy of morphine and locomotor deficits.  In our study, however, 
                                                
2 Reprinted with permission from “Opioid administration following spinal cord injury: 
implications for pain and locomotor recovery” by S.A. Woller & M.A. Hook, 2013. 
Experimental Neurology, in press. Copyright (2013) by Elsevier. 
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we failed to find significant effects of SCI or morphine administration on spinal KOR 
protein or TNFα.  A contusion injury significantly increased caspase-3 protein 48-hours, 
but not 8-days after SCI, and morphine administration had no additional effect.  These 
experimental results will be discussed below in regards to addiction, recovery of 
locomotor function, and the development of pain. 
Consequences of Opioid Administration After SCI: Addiction 
 In these experiments, we examined the abuse liability of morphine in the acute 
and chronic phases of SCI.  In the acute phase of injury, we found dose-dependent 
effects on morphine self-administration.  Animals given access to 1.5 mg morphine self-
administered significantly less morphine than sham controls.  In contrast, animals given 
access to a higher dose, 3.0 mg / infusion, increase intake over the first 3 sessions to 
administer nearly the full amount of morphine available on days 4-7, a behavior 
indicative of addiction.  In the early chronic and chronic phases of injury, however, this 
difference did not persist.  Contused animals given access to 1.5 mg morphine 
administered nearly the full amount available each session in the early chronic phase of 
SCI.  In the chronic phase, a similar pattern emerged.  Contused animals self-
administered nearly the full amount of morphine available each session, suggesting that 
morphine reward is altered in the acute, but not the chronic, phase of SCI. 
Acute Pain and Morphine Reward 
Previously, we hypothesized that increases in spinal dynorphin levels, resulting 
from morphine administration and SCI, activate spinal KORs to oppose morphine-
induced analgesia, and decrease reward (decrease morphine self-administration).  
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Indeed, as was discussed in Chapter IV, the difference in self-administration between the 
acute and chronic phases of SCI may be due to decreased analgesic efficacy of 
morphine, making the 1.5 mg dose less rewarding in the acute phase than the chronic.  It 
would, therefore, not maintain morphine self-administration.  In our analyses of protein 
expression of the kappa opioid receptor, however, we failed to see significant differences 
at a spinal level.  This alone does not, however, rule out a role for a kappa-mediated 
reduction in the potential for addiction after SCI. While we did not see spinal changes in 
the KOR, increased dynorphin activation of the KOR does not necessarily lead to an 
alteration in the number of KORs (Faden, 1990; Faden et al., 1985, Abraham et al., 
2001).  In addition, while spinal changes in KOR activation could decrease reward from 
an analgesic standpoint, supraspinal sites are involved in addictive processes, and 
changes in these systems were not examined.   
Indeed, in the current studies, we administered i.v. morphine, which will bind at 
spinal and supraspinal sites.  Exposure to drugs of abuse, such as morphine, increases 
striatal dynorphin levels and KORs (see Butelman et al., 2012 and Niikura et al., 2010).  
As with spinal activation, increased activation of the KOR is also thought to oppose 
reward at a supraspinal level (see Niikura et al., 2010).  For example, genetic differences 
in brain dynorphin levels have been shown to make various strains of mice less 
responsive to the rewarding effects of morphine (Gieryk et al., 2010).  Mouse strains 
with high endogenous levels of dynorphin will not develop a preference for a morphine-
paired context at a low dose of morphine.  When the KOR is antagonized with nor-BNI, 
the same dose of morphine will produce a conditioned place preference (Gieryk et al., 
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2010).  Furthermore, it is known that dynorphin binds to KOR in the nucleus accumbens 
(NAcc) to decrease dopamine (DA) levels, supporting the idea that activation of the 
KOR antagonizes reward, even at supraspinal sites (Di Chiara & Imperato, 1988; 
Skoubis et al., 2001; Spanagel et al., 1990).  This antagonistic effect, however, varies 
with the cycle of addiction. 
There are differential effects of MOR receptor activation with and without 
concurrent KOR activation.  When MOR’s are activated along with KOR’s (as in 
analgesic use following SCI), the activation of the KOR is though to “protect” from 
addiction, by opposing MOR-mediated reward.  However, in the absence of MOR 
activation, KOR agonists are known to produce dysphoria (Aldrich, 2003) and are 
aversive to rodents (Shippenberg et al., 2001).  In the withdrawal / abstinence stage of 
addiction (when there is no MOR activation), the dysphoria associated with increased 
KOR activation is thought to underlie drug seeking.  In addition, conditions of stress can 
contribute to increases in dynorphin levels, and, therefore, KOR activation.  Stress-
induced anxiety and increases in dynorphin levels increase the risk of drug abuse in 
people (de Kloet et al., 2005) and reinstate drug seeking in animals (Shaham et al., 
2000).  These data indicate that, rather than protecting from addiction, increased levels 
of dynorphin can contribute to drug relapse.  Following SCI, the stress related to 
sustaining the injury (i.e. the numerous consequences associated with injury affecting 
quality of life) could potentially lead to increased risk of drug abuse, in patients with a 
prior history of drug use. 
  135 
Indeed, in our rodent model of SCI, we have studied the development of 
addictive behavior under ideal conditions.  Our animals have no prior experience with 
drugs of abuse.  How prior exposure to drugs of abuse affects addiction in the SCI model 
is an important question. In the general population, opioid abuse and addiction have 
become quite prevalent, especially among people aged 12-25 (NIDA, 2011). According 
to statistics published by the Christopher Reeve Foundation (2009), the majority of 
people will sustain a spinal cord injury between 25-40 years of age, making it likely that 
these individuals will have prior history with drugs of abuse.  Indeed, Heinemann et al. 
(1988) found that up to 62% of SCI patients had misused drugs or alcohol at the time of 
their injury.  This history with drugs of abuse makes finding adequate therapies to treat 
pain difficult, and makes these individuals susceptible to the development of addiction 
when using opioids for the treatment of pain following SCI.  These are issues that need 
to be further addressed. 
In addition to the role of the KORs in analgesia and addiction, MORs also play a 
role.  Traditionally, agonists of MORs, are associated with the analgesic properties of 
morphine.  In the last experiment, however, we found that a contusion injury 
significantly decreased spinal MOR protein levels.  Thus, decreased analgesic efficacy 
of morphine in the acute phase of injury could result from a decreased number of MORs.  
Indeed, it has been shown contused rats require a higher dose of intrathecal morphine to 
produce antinociception (Hook et al., 2009).  Whether similar changes occur at a 
supraspinal level as a result of injury have yet to be investigated, but are quite possible 
and would have implications for pain control and addiction. 
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Neuropathic Pain and Morphine Reward 
 Despite the highly addictive nature of opioids, there is evidence to suggest that a 
state of neuropathic pain will decrease the risk of addiction to opioids used for treatment 
(e.g. Minozzi et al., 2013; Niikura et al., 2008; Martin et al., 2007; Ewan & Martin, 
2011; Niikura et al., 2010).  Indeed, when separating animals by pain state, contused 
animals experiencing neuropathic pain trended toward a decrease in morphine self-
administration relative to their pain-free counterparts.  While this result was not 
significant, there was an unequal sample size, leaving only 2 rats in the pain-free 
condition.  There is a need for additional work examining the effects of pain on 
morphine self-administration because it has been shown that pain alters supraspinal 
reward circuitry.  For example, Ozaki et al. (2003) have shown that morphine-induced 
release of dopamine (DA) in the nucleus accumbens (NAcc) is reduced following sciatic 
nerve ligation (SNL), indicating a reduction in reward potential in animals experiencing 
neuropathic pain.  In addition, chronic morphine administration has been shown to 
increase ERK activation in the ventral tegmental area (VTA), where it increases 
activation of tyrosine hydroxylase (TH; Berhow et al., 1996).  Tyrosine hydroxylase is 
necessary for the synthesis of dopamine.  Thus, ERK activation, occurring as a result of 
chronic morphine administration, in the VTA stimulates DA production.  However, 
following SNL, levels of p-ERK following morphine administration are significantly 
decreased (Ozaki et al., 2004), leading to a decrease in opioid reward due to decreased 
dopamine availability.  Whether similar changes occur as a result of SCI-induced 
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neuropathic pain, and with morphine administration have yet to be investigated, but, is 
important from a clinical standpoint. 
Tolerance 
 
 Morphine reward can also be affected by the development of tolerance.  In the 
final experiment (Chapter V), we examined the development of tolerance to morphine 
following the repeated administration of high doses.  We found evidence of tolerance 
developing on days 5-7 of administration.  In previous experiments (Chapter III), we 
were unable to say whether morphine administration was increasing in the acute phase of 
injury due to the development of addiction, or tolerance.  In the 3.0 mg / infusion 
animals, we saw an escalation in the amount of morphine self-administered beginning on 
day 3, and these animals reached the same level of administration as sham controls by 
day 4.  With experimenter-controlled administration of morphine, however, signs of 
tolerance did not begin to develop until the 5th day of administration, suggesting animals 
are increasing their intake for reasons other than the development of tolerance.  
However, the development of tolerance could maintain the high rates of administration 
seen on days 5-7.  This is concerning because the clinical SCI population is faced with 
long-term, high-dose opioid treatment.  The development of tolerance in these 
individuals will result in increased opioid intake, further increasing their risk of 
experiencing significant side effects such as respiratory suppression, sedation, and 
attenuated recovery of locomotor function when treatment is initiated in the acute phase 
of SCI.  
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 Together, these studies suggest morphine administration and neuropathic pain 
can cause alterations at a spinal and supraspinal level to influence the rewarding 
properties of morphine.  This can result from decreased analgesic efficacy, decreased 
release of dopamine, and the development of tolerance.  These issues make the use of 
opioids for the treatment of chronic pain more likely to lead to drug-seeking behaviors.  
In addition to these concerns, however, opioid administration has also been shown to 
affect recovery of locomotor function in experimental models.  
Consequences of Opioid Administration After SCI: Attenuation of Locomotor 
Recovery 
Previous studies have shown morphine administration undermines recovery of 
locomotor function (Hook et al., 2009; 2011).  In these studies, morphine was applied 
directly to the spinal cord, a route of administration that is not frequently used clinically.  
In the current studies, we used a clinically relevant, intravenous delivery of morphine.  
Intravenous infusions are similar to patient controlled analgesia used in hospital settings.  
Using this route of administration, we found that morphine administration significantly 
undermines recovery of locomotor function in the acute phase of SCI.  This effect, 
however, was dependent on the amount of morphine being administered.  Animals 
administering on average 50+ mg/kg/day showed significantly impaired recovery.  
Those administering less, recovered to the same level as saline controls.  In the current 
studies, impaired recovery was associated with significantly increased lesion size.  
Surprisingly, however, in the chronic phase of injury all contused animals self-
administered more than 50 mg/kg/day and did not show an attenuation of locomotor 
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recovery.  This suggests the spinal cord is more vulnerable to the effects of morphine 
administration in the acute, rather than the chronic, phase. 
As discussed previously, it was hypothesized that increased dynorphin levels, 
resulting from injury and morphine administration would increase activation of the KOR 
to increase excitotoxicity and paralysis.  In intact rats, increases in spinal dynorphin are 
associated with locomotor deficits (paralysis) (Faden & Jacobs, 1984; Faden, 1990; 
Bakshi et al., 1992), and spinal cord injury is known to cause an increase in dynorphin 
levels (Faden et al., 1985; Przewlocki et al., 1988; Yakovlev & Faden, 1994), 
contributing to the secondary pathology of injury.  We would expect to see the greatest 
synergistic effect of opioid administration and SCI in the acute phase of injury, when 
endogenous dynorphin levels are still increased as a result of sustaining the injury, 
leading to the pattern of results we observed.  Indeed, a study by Adjan et al. (2007) 
found that dynorphin, following a T10 contusion injury in mice, is associated with the 
expression of caspase-3 in greater than 90% of all neurons, oligodendrocytes, and 
astrocytes.  These differences were seen at 4 hours, but not 24-hours following SCI 
(Adjan et al., 2007).  Thus opioid administration, which also increases dynorphin levels, 
is likely to have the greatest synergistic effect when applied soon (within the first 24 
hours) after injury.   
While we saw behavioral effects of morphine administration, we did not see 
changes in KOR or caspase-3 protein following 8 days of morphine administration.  
However, we were assessing changes in protein following 7 days of morphine 
administration, and the tissue was collected 8-days following injury.  This is definitely 
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outside the window in which Adjan et al. (2007) reported significant increases in 
caspase-3.  Similarly, we had a group of animals in which we assessed changes in 
protein levels 24-hours after morphine administration, and 48-hours after a contusion 
injury.  In this group of animals, there was a significant increase in caspase-3 protein, 
especially in the contused animals treated with morphine.  Together, these results 
suggest that morphine administration is having an immediate effect, and there is not an 
additional effect with increased morphine administration.  In fact, it is possible that the 
morphine administered within the first 24-hours of injury is leading to these detrimental 
effects.  It is imperative that this issue is examined and the effects of morphine 
administration following SCI are assessed at an earlier time following morphine 
administration. 
While increased activation of the KOR may be producing an immediate effect to 
decrease recovery of locomotor function, glial activation, resulting in the release of pro-
inflammatory cytokines (such as IL-1β) has also been shown to affect recovery of 
locomotor function (Hook et al., 2011).  As with alterations in dynorphin levels, 
increased glial activation is also characteristic of the acute phase of SCI.  In fact, 
following SCI, astrocytes in the thoracic spinal dorsal horn are most activated from 24-
hours to 7-days post injury, and microglia are most activated at 24-hours (Gwak et al., 
2012). Upon activation, glial (actrocytes and microglia) cells, rather than maintaining 
homeostasis, become dysfunctional and contribute to neuronal hyperexcitability (Gwak 
& Hulsebosch, 2009).  Morphine administration can contribute to dysfunction through 
binding at TLR4.  In fact, we found a significant increase in spinal TLR4 protein levels 
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following SCI, likely due to increases in glia in the injured spinal cord.  Upon activation, 
glial cells release pro-inflammatory cytokines (IL-1β and TNFα) that contribute to 
inflammation and secondary damage (Pineau & Lacroix, 2007; Nesic et al., 2005; 
Donnelly & Popovich, 2008; Song et al., 2001; Choi et al., 2010).  Increases in pro-
inflammatory cytokine levels cause further activation of glial cells.  In this cycle, 
exacerbating glial activation (and levels of pro-inflammatory cytokines) through the 
administration of morphine can produce detrimental effects.  In these experiments, we 
did not find significant differences in the overall levels of TNFα following morphine 
administration or SCI, suggesting TNFα is not contributing to this cycle of glial 
activation and cell damage.  However, SCI has been shown to increase the levels of IL-
1β, and morphine administration further increases the levels of IL-1β (Hook et al., 
2011).  It is thought that the increased IL-1β is contributing to the deficits in locomotor 
function associated with morphine administration.  This is supported by data showing 
antagonizing the IL-1 receptor prior to morphine administration blocks the attenuation of 
locomotor function (Hook et al., 2011).   
Changes in glial activation and the release of pro-inflammatory cytokines are not 
characteristic of the chronic phase of SCI.  While glial activation continues for up to 180 
days following SCI (Gwak et al., 2012), and increases in pro-inflammatory cytokines are 
seen up to 28 days, the levels are not as high as in the acute phase of SCI.  In addition, it 
is unlikely that any one of the processes affecting the acute phase of SCI is causing 
deficits in locomotor function alone.  Rather, it is likely a combination of all factors that 
push the system to hyperexcitability, and dysfunction.  Thus, morphine administration, 
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in the chronic phase of SCI, does not contribute as significantly to dysfunction as it does 
in the acute phase.  This indicates that, aside from concerns of addiction, morphine use 
for the treatment of pain in this phase of injury will not affect recovery of locomotor 
function. 
Consequences of Opioid Administration After SCI: Pain 
Pain is a common consequence of SCI, and is often treated with opioid 
analgesics.  Unfortunately, long-term treatment with opioids can, paradoxically, lead to 
the development of pain.  In these experiments, we assessed the development of opioid-
induced hyperalgesia, and the effects of opioid administration on pain reactivity long 
after cessation of administration.  Following repeated administration of morphine, we 
saw the development of OIH, but there was no lasting effect of morphine administration 
in the chronic phase of injury.  Contused animals show increased reactivity at the end of 
the 42-day period relative to sham animals, but there was not a difference between 
contused animals treated with morphine versus those treated with saline.  This was true 
of morphine administration in the acute and chronic phases of SCI.  These results 
suggest spinal cord injury is not affecting the development of OIH, as both contused and 
sham animals showed signs of increased reactivity following repeated morphine 
administration, and that morphine administration is not leading to long-lasting changes 
in pain reactivity after the cessation of use.  
The development of OIH, limits the clinical utility of morphine (Tawfic et al., 
2013).  In addition, opioid-induced hyperalgesia and the development of tolerance are 
difficult to distinguish in a patient population, and treatment of each differs.  While 
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tolerance requires escalating doses of morphine to relieve reports of increased pain, OIH 
requires a reduction (Mao et al., 2002).  Animal models are needed to identify molecular 
biomarkers, and the causal mechanisms, associated with these two distinct phenomena. 
Research examining the development of tolerance and OIH has often focused on shared 
mechanisms, specifically spinal dynorphin, increased glutamate availability (leading to 
NMDA-mediated excitation), and, more recently, glial activation (Mao et al., 2002; 
Vanderah et al., 2001; Ferrini et al., 2013).  This recent research indicates that the 
tolerance and OIH result from separate mechanisms.  For example, Ferrini et al. (2013) 
have demonstrated a role of spinal microglia in the development of OIH, but not 
tolerance. They showed morphine administration activated microglia and stimulated the 
release of brain-derived neurotrophic factor (BDNF) (Ferrini et al., 2013).  This led to 
impaired Cl- homeostasis in the spinal dorsal horn, resulting in hyperalgesia (Ferrini et 
al., 2013).  This pathway has also been implicated in the development of hyperalgesia 
independent of opioid administration (Trang et al., 2011).  Further understanding of 
these phenomena is important for the continued use of morphine in the treatment of 
chronic pain. 
General Health Concerns 
 Although spinal cord injury directly damages tissue at the level of the spinal cord 
only, its effects are seen throughout the CNS and periphery.  While this dissertation 
focused on the neuronal and glial effects of opioid administration following SCI, it 
should be noted that SCI also induces a number of changes that can decrease the overall 
health of the individual.  If fact, a leading cause of death in both the acute and chronic 
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phases of SCI is cardiovascular disease (Furlan & Fehlings, 2008; Popa et al., 2010).  In 
addition, individuals can experience changes in blood pressure, heart rate, blood flow, 
hypotension, bradycardia, deep vein thrombosis, and are at long-term risk for coronary 
heart disease and athrosclerosis (see Furlan & Fehlings, 2008; Popa et al., 2010; 
Grigorean et al., 2009 for review).  Several of these metrics, specifically, blood pressure, 
heart rate, and body temperature have been shown to be altered by morphine 
administration in an experimental setting (Froger-Colléaux et al., 2011).  These changes 
can significantly impact the health of the individual.  Additionally, patients with a 
cervical or high thoracic (above T6) injury will frequently experience autonomic 
dysreflexia, which is characterized by an increase in blood pressure in response to 
stimulation (noxious or not) below the level of injury, often bowel or bladder distension 
(Rabchevsky, 2006; Weaver et al., 2002; Weaver et al., 2006).  This sudden increase in 
blood pressure, while often within normal limits for healthy individuals, can be life-
threatening (Furlan & Fehlings, 2008) in individuals with SCI.  This is also problematic 
in individuals not experiencing autonomic dysreflexia.  
 Similarly, in a population susceptible to bladder infections, pressure ulcers, 
pneumonia, gastrointestinal infections, and frequent hospitalizations, immune 
suppression is dangerous.  If fact, infections are the leading cause of death in individuals 
with cervical or high thoracic injuries (DeVivo et al., 1989).  In the SCI population, 
immune (non-microglial / astrocyte responses) suppression results from dysregulation of 
the hypothalamic-pituitary-adrenal (HPA) axis.  Morphine may further reduce the 
systemic immune response by decreasing lymphocyte levels (Weed et al., 2006).  
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Clinically, the effects of morphine on immunosuppression are also quite clear 
(Eisenstein et al., 2006; Mellon & Bayer, 1998; Odunayo et al. 2010) as an opioid-
induced immune suppression is thought to play a role in the increased incidence of 
bacterial infections in heroin addicts (Zhang et al., 2008).  Experimentally, increased 
bacterial infection is also evident in the liver, spleen, kidneys, heart, and lungs of mice 
receiving morphine (Zhang et al., 2008).  Imposing opioid-induced immune suppression 
onto a population vulnerable to infections should be considered before beginning 
treatment with an opioid.  
 These are not the only concerns when using morphine for pain relief.  In our 
experiments, morphine treatment led to weight loss in contused and sham animals 
(Chapters III – V).  Administration of a high amount of morphine was associated with 
the greatest loss.  Typically, chronic morphine administration is associated with weight 
loss occurring as a result of decreased food intake (Nogueiras et al., 2012).  In these 
animals, however, we did not see a difference in food intake during the period of self-
administration, when the most robust weight loss occurred.  It is possible that we did not 
get an accurate measure of food intake because all animals were on a disrupted schedule.  
During the self-administration sessions, animals were removed from their home cages 
for 12-hours, during their active cycle.  Thus, all animals could have decreased their 
food intake, even those administering saline, resulting in the lack of differences between 
groups.  Indeed, even saline animals show weight loss during the 7-days associated with 
self-administration sessions (Figure 20).  Altered food intake, however, is not the sole 
cause for weight loss in these animals.  Hook et al. (2009, 2011) have shown a single 
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intrathecal administration of morphine also induced lasting weight loss.  Though it has 
not been examined in the experiments mentioned, this treatment should not affect food 
intake.  On the contrary, acute treatment with opioids has been shown to increase food 
intake (Levine et al., 1988), leaving other factors responsible for this weight loss.   
 Alternatively, weight loss can occur as a part of withdrawal syndrome (Gue et 
al., 2005), which may contribute to the weight loss we observed in the early chronic 
phase of injury.  Indeed, the high amounts of morphine led to signs of withdrawal (e.g. 
wet dog shakes, teeth chewing) throughout the period of administration and into the 
recovery period.  However, as mentioned above, a single intrathecal administration of 
morphine also results in a lasting weight loss, and this treatment does not lead to 
withdrawal.  Thus, it is unlikely that withdrawal is the sole contributor to weight loss.   
 Weight loss associated with morphine administration is commonly seen, but the 
typical explanations for this loss do not hold in our studies.  We propose, instead, 
morphine administration is affecting metabolic and physiological variables and 
increasing weight loss.  For instance, chronic morphine treatment results in decreased 
caloric efficiency (Ferenczi et al., 2010), increased body temperature, increased heart 
rate, increased arterial blood pressure (Froger-Colléaux et al., 2011), and alterations in 
blood brain barrier permeability (Sharma & Ali, 2006; Lynch & Banks, 2008).  How 
these factors affect weight following morphine administration in the SCI model need to 
be investigated.   
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Clinical Implications 
 Opioids have long been a standard in the treatment of pain following SCI.  In the 
chapters above, however, we have shown that opioid administration can interact with 
SCI pathology to negatively impact locomotor recovery.  In the absence of descending 
inhibition, the spinal cord may be particularly vulnerable to increased levels of 
glutamate, resulting in NMDA-mediated excitotoxicity initiated by classic and non-
classic opioid receptor activation, and resulting in detrimental effects.  Nonetheless, for 
patients faced with a lifetime of intractable pain, opioids as effective analgesics cannot 
simply be removed as a treatment.  For this reason, continued research is needed to 
develop guidelines for the safe use of these agents following SCI. 
 Indeed dose-dependent effects on recovery of locomotor function have been seen 
with morphine administration via either an intrathecal or intravenous route.  Hook et al., 
(2009) found that a single 90 µg, but not 30 µg, intrathecal administration of morphine 
attenuates recovery of locomotor function.  Similarly, we have shown that administration 
of high amounts of intravenous morphine, a more clinically relevant route of 
administration, also results in the attenuation of locomotor function and decreased 
weight, while the administration of lower amounts only results in weight loss.  
Considering there is no maximum dosage for opioids, and patients are often started on 
10-15 mg morphine every 4 hours, often up to 300+ mg a day (Magrinelli et al., 2013) 
for the treatment of pain, this result is concerning.  Together, this data suggests that high 
doses of morphine administered either intrathecally or intravenously in the acute phase 
can have adverse consequences on recovery of locomotor function following 
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experimental SCI.  Doses given clinically in this phase of injury should be monitored 
carefully. 
 Equally important is the time at which opioid administration begins.  The acutely 
injured spinal cord environment differs from that of the chronic phase.  As discussed, 
opioid administration in the acute phase can exacerbate the pathology (e.g. increase 
excitotoxicity, increase glial activation) of SCI.  In the chronic phase of injury, however, 
many of the inflammatory and endogenous opioid responses have subsided.  Indeed, 
administration of opioids in the chronic phase of SCI does not lead to an attenuation of 
recovery of locomotor function.  While this data suggests opioid administration may not 
be detrimental to recovery of locomotor function, opioid administration led to addictive 
behavior in these experiments.   Because of this risk, opioids have been downgraded to a 
second-line medication for the treatment of pain (Attal et al., 2010).  It has also been 
suggested that opioids are not an effective-long term treatment in SCI patients, and that 
morphine should be removed as a treatment option (Smith & Meek, 2011). 
 Apart from monitoring dose, route, and phase of injury in which morphine is 
administered, research is needed to examine potential drug combinations that can 
improve the analgesic efficacy of morphine while preventing the negative (e.g. 
decreased locomotor function, development of tolerance) consequences.  Studies have 
shown that administration of an NMDA antagonist is an effective treatment for 
attenuation of both neuropathic pain and recovery of locomotor function.  This 
treatment, however, is associated with unwanted side effects such as hallucination, 
dysphoria, and locomotor deficits, making it unsuitable for clinical use.  In addition, 
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while an NMDA antagonist has been successful in promoting recovery of function in 
animal models (Lonjon et al., 2010), the success in clinical trials is yet to be determined 
(Kwon et al., 2010).  Thus, it is important to look at alternative therapies.  For instance, 
Kim et al. (2012) found that treatment with an NR2B subunit specific antagonist 
produces fewer unwanted side effects and reverses mechanical allodynia when 
administered two weeks following a contusion injury.  In addition, a number of studies 
have shown that treatment with an antagonist for the NR2B subunit blocks morphine-
induced reward (Ma et al., 2006a, Ma et al., 2011; Narita et al., 2000).  For instance, Ma 
et al. (2006a) showed that treatment with Ifenprodil, an antagonist specific for the NR2B 
subunit of the NMDA receptor, decreased a morphine-induced conditioned place 
preference.  The same treatment did not decrease a place preference for natural 
reinforcers (e.g. food consumption or social interaction).  Thus, coadministration of an 
NR2B subunit antagonist with morphine could be a potential treatment for pain 
following SCI and could lower the abuse potential of morphine. 
 In addition, activation of TLR4 is responsible for many of the negative effects of 
morphine administration.  It has been demonstrated that blockade of TLR4 increases 
opioid efficacy (Hutchinson et al., 2007; Johnston et al., 2004), and blocks other 
negative effects of opioids such as respiratory depression (Hutchinson et al., 2008a; 
2008b; 2008c).  Yet, as discussed previously, while blocking TLR4 can decrease pain 
and increase efficacy, it can contribute negatively to recovery of locomotor function 
after SCI.  Potentially, if the blockade of TLR4 activity was via selective inhibition of 
microglia (e.g. blockade with minocycline), it may prove an effective treatment strategy.  
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The timing of administration of a TLR4 antagonist may also be critical: administration 
of an antagonist may be beneficial in conjunction with morphine in the chronic, but not 
acute phase of injury.  Whether antagonizing TLR4 with (+)-naloxone can be used 
repeatedly with morphine for the treatment of pain (and prevention of addiction) has yet 
to be determined.  As combination drug therapies are being used for the treatment of 
chronic pain with some success (for review, see Mao et al., 2011), these possibilities 
need to be explored. 
 Given the numerous negative consequences associated with opioid 
administration in the spinally injured population, clinical opioid use must be further 
evaluated and refined.  However, the use of opioids is not only relevant to SCI pain.  
Central pain resulting from stroke, or TBI, falls under the same treatment guidelines as 
those for pain resulting from SCI.  While the pathology differs from that of SCI, there 
may be similar concerns related to opioid use in other central models of pain or disease 
that need to be considered before initiation of an opioid treatment regimen.  
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